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INTRODUCTION 
Peripheral Vascular Disease (PVD), or Peripheral Arterial disease, is one of the 
major causes of morbidity and mortality in the Indian population, the prevalence 
increasing in elderly and diabetic people. Chronic lower extremity ischemia is the most 
common cause of loss of walking ability attended by a vascular surgeon and is associated 
with a constellation of disorders affecting the entire system1. Atherosclerotic PVD is a 
prototype of chronic systemic atherosclerosis and is characterized by arterial stenoses and 
occlusions in the peripheral arterial bed of lower limbs. The various risk factors include 
Age, DM, Smoking, hypertension, hyperlipidemia, hyperhomocysteinemia etc. 
  Atherosclerosis is a chronic inflammatory disease. Cardiovascular atherogenicity 
is the major cause of mortality around the world, though it can effect all the medium and 
large sized vessels in the body.  Dyslipidemia is a major risk factor for the development 
and progression of atherosclerosis, along with the life style and co morbid conditions like 
Diabetes mellitus. The major lipids of human body are phospholipids, cholesterol, 
triglycerides and cholesteryl esters. These insoluble lipids are transported through the 
blood as lipoprotein complexes of lipids and one or more of specific proteins called 
apolipoproteins. By actively exchanging certain lipids and apolipoproteins with each 
other, the lipoproteins are synthesized and degraded at a constant rate. Among 
lipoproteins, low density lipoproteins (LDL) has 75% lipid and 25% proteins. 
Modification of LDL, mainly Oxidation, plays a key role in the evolution of 
atherosclerosis. High density lipoprotein (HDL) has a protective role in atherosclerosis, 
because it is involved in reverse cholesterol transport and helps to excrete cholesterol by 
the liver. Another role of HDL in protection against atherosclerosis is by inhibiting the 
oxidative modification of LDL. 
Lipoprotein(a) is a genetically determined, cholesterol rich plasma lipoprotein 
which is a risk factor for atherosclerosis. High Lp(a) concentration represents an indicator 
of risk for cardiovascular disease, especially when serum LDL-cholesterol or Apo B are 
elevated.  Lp(a) levels are found to be resistant to standard lipid lowering therapy, with 
the exception of Niacin.  
Lp(a) consists of an LDL-like particle and the specific apolipoprotein(a) [apo(a)], 
which is covalently bound to the apoB100 of the LDL like particle through disulphide 
bridges. Lp(a) causes atherogenesis due to the LDL particle and leads to thrombogenesis 
due to its structural homology with plasmoinogen, thereby promoting the development of 
atherosclerotic plaques. Lp(a) also stimulates smooth muscle proliferation of the affected 
blood vessels. One proposed mechanism by which it is done is by inhibiting the 
activation of Transforming Growth Factor-β. 
Transforming Growth factor type-β (TGF-β) is a superfamily of ligands, receptors 
binding proteins and ligand traps that together plays a key role in maintaining the normal 
vessel wall structure by inhibiting smooth muscle proliferation. TGF-β is found to play a 
crucial role in the development and/or regression of malignant tumors, autoimmune 
diseases, organ fibrotic changes, kidney diseases and cardiovascular diseases. It exists in 
three known subtypes in humans TGF-β1, TGF-β2 and TGF-β3. TGF-β1 is present in 
endothelial cells, vascular smooth muscle cells (VSMCs), myofibroblasts, macrophages, 
and other hematopoietic cells. It is recognized as the most pivotal TGF-β isoform for the 
cardiovascular system 
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REVIEW OF LITERATURE 
Peripheral Vascular disease, commonly referred to as peripheral arterial disease 
(PAD) or peripheral artery occlusive disease (PAOD), refers to the obstruction of large 
arteries not within the coronary, aortic arch vasculature, or brain. PVD can result from 
atherosclerosis, inflammatory processes leading to stenosis, an embolism, or thrombus 
formation2. Peripheral arterial disease causes limb pain with exertion, reduces functional 
capacity and quality of life, and is frequently associated with coronary, cerebral, and 
renal artery disease . Individuals with PAD are at increased risk for acute cardiovascular 
events such as myocardial infarction, cerebrovascular attack, aortic aneurysm rupture, 
and vascular death, as well as ischemic ulceration and amputation . This increased risk 
for cardiovascular morbidity and mortality is seen even in patients without symptoms3. 
Several population-based studies based on predominantly white European populations 
have found the prevalence of PAD to be between 6% and 18% over the age of 55 years. 
The prevalence rises with age and has been found to be approximately 20% in people 
over 70 years of age and up to 60% in the over 85 age group. 
There has, however, been very little research into the prevalence of PAD in non-
Caucasian populations, although previous population-based studies have shown 
variations in the prevalence of this disease amongst different ethnic groups4. Peripheral 
vascular disease affects 1 in 3 diabetics over the age of 50. 70%–80% of affected 
individuals are asymptomatic; only a minority ever requires revascularisation or 
amputation. 
 
 
Classification5 
 Fontaine stages of peripheral arterial disease 
 mild pain when walking (claudication), incomplete blood vessel obstruction; 
 severe pain when walking relatively short distances (intermittent claudication), 
pain triggered by walking "after a distance of >150 m in stage IIa and after <150 
m in stage IIb" 
 pain while resting (rest pain), mostly in the feet, increasing when the limb is 
raised; 
 Biological tissue loss (gangrene) and difficulty walking. 
 Rutherford classification is a recent classification system and it consists of three grades 
and six categories: 
1. Mild claudication 
2. Moderate claudication 
3. Severe claudication 
4. Ischemic pain at rest 
5. Minor tissue loss 
6. Major tissue loss 
 Symptoms2 
About 20% of patients with mild PAD may be asymptomatic; other symptoms include 
 Claudication - pain, weakness, numbness, or cramping in muscles due to 
decreased blood flow 
 Sores, wounds, or ulcers that heal slowly or not at all 
 Noticeable change in color (blueness or paleness) or temperature (coolness) when 
compared to the other limb (termed unilateral dependent rubor; when both limbs 
are affected this is termed bilateral dependent rubor) 
 Diminished hair and nail growth on affected limb and digits. 
The incidence of symptomatic PVD increases with age, from about 0.3% per year for 
men aged 40–55 years to about 1% per year for men aged over 75 years. The prevalence 
of PVD varies considerably depending on how PAD is defined, and the age of the 
population being studied. Diagnosis is critical, as people with PAD have a four to five 
times higher risk of myocardial infarction or stroke. 
Diagnosis of PVD6 
Conventionally PVD is diagnosed by measuring the Ankle Brachial Pressure Index 
(ABPI) or Ankle Brachial Index (ABI) 
Calculation of ABI: 
Ankle systolic Pressure 
ABI = 
Highest Brachial systolic pressure 
 
 
>/= 1 : normal 
0.5 to 1 : moderate disease 
< 0.5 : severe disease 
<0.3 : critical limb ischemia 
PAOD is diagnosed when the ABI is <0.9. 
Other techniques used for diagnosis are2 
- Doppler ultrasound imaging 
- Angiography 
- Multislice computerised tomography (CT) scan. 
Causes of PVD 
ATHEROSCLEROSIS 
Atherosclerosis accounts for most peripheral arterial occlusive disease. Many of 
the risk factors for atherosclerotic coronary artery disease (CAD) such as hyperlipidemia 
have been identified as risk factors for peripheral arterial disease. Atherosclerosis is a 
complex disease in which numerous diverse etiologic factors play a role. The most 
widely accepted concept of genesis of atherosclerosis is that intimal injury incites a series 
of reactions, which ultimately culminate in development of fibrous plaques. This is the 
"response to injury" hypothesis6. (fig 1) 
 Fig 1 : Evolution of arterial wall changes and plaque formation in the 
response-to-injury hypothesis 
 
 
1.  Endothelial dysfunction; 2,; 3,; 4,; 5,; 6,; 7,; 8,  
2. vascular smooth muscle cell (VSMC) hypertrophy 
3. migration and proliferation of VSMCs 
4. matrix elaboration 
5. expression of adhesion molecules and migration of monocytes 
6. uptake of low-density lipoprotein (LDL) and formation of foam cells 
7. thrombus formation 
8. angiogenesis and neovascularization 
 
 
 
 
Atherosclerosis is defined as an intimal disease of large and medium sized arteries 
of external diameter more than 2 mm7. There is focal accumulation of lipid and smooth 
muscle cell proliferation producing lesions called plaques which begin mostly in the 2nd 
or 3rd decade of life8. Every plaque has 2 major constituents namely, the lipid and the 
extra cellular matrix proteins. Collagen produced by the smooth muscle cells is the 
predominant protein here. The nature and composition of these plaques change as they 
evolve.  
Atherosclerosis reflects a continuing repair process occurring in the arterial wall 
secondary to persistent arterial injury. The injurious factors could be multifactorial and 
include hyperlipidemia, shear stress, hypertension, and cigarette smoking. The common 
denominator is endothelial injury. (Fig 2) This results in accumulation of blood-borne 
monocytes, which migrate into the subendothelial space. Such monocytic accumulation is 
one of the earliest detectable precursors in the genesis of atherosclerotic lesions. Within 
the subendothelial space the monocytes convert into cholesterol-laden foam cells. This 
accumulation distorts the endothelial covering, causing microseparation of endothelial 
cells and platelet deposition. Smooth muscle cells migrate into the intima from the media, 
also converting into foam cells7.  
 
 
 
 
 Fig 2 : Consequences of Endothelial Dysfunction 
 
Normal endothelium displays antiaggregant, anticoagulant, and vasodilatative properties, 
along with inhibition of cell proliferation. After exposure to various agents causing 
endothelial dysfunction, these functions are modified toward procoagulant and 
vasoconstrictive activities together with stimulation of cell recruitment and proliferation. 
 LDL- low-density lipoprotein 
 NO- nitric oxide 
 PAF- platelet-activating factor 
 PAI-1- plasminogen activator inhibitor-1 
 PGI2- prostacyclin 
 ROS- reactive oxygen species 
 SMC-smooth muscle cell 
 TXA2, thromboxane A2. 
T lymphocytes recruited to the intima interact with macrophages and can generate a 
chronic immune inflammatory state. The T lymphocytes found in atherosclerotic lesions 
are polyclonal, which indicates that these cells do not develop in response to a single 
antigen9. Activation of complement seems to play a role in both initiation of 
atherosclerosis and acceleration of the disease. Complement activation can occur by 
either the classical (antibody dependent) or the alternative (antibody independent) 
pathway. Cholesterol particles have been shown to be potent complement activators. 
Proliferation plus activation of VSMCs and endothelial cells is also mediated by 
activation of complement10. 
Platelets play an important role in stimulating the progression of atherosclerotic lesions 
by secreting growth factors and vasoactive substances (e.g., platelet-derived growth 
factor [PDGF], transforming growth factor-α [TGF-α], TGF-β, epidermal growth factor 
[EGF], and insulin-like growth factor-I [IGF-I]) after their adherence to the vessel wall in 
sites of endothelial ulceration11. Recently, platelets have been suggested as initial role 
players in the development of atherosclerotic lesions by recruiting and binding to 
leukocytes, endothelial cells, and circulating progenitor cells and initiating transformation 
of monocytes into macrophages. Platelets internalize oxidized phospholipids, express 
various scavenger receptors that are able to regulate LDL uptake, and promote foam cell 
formation12.  
The fatty streak is the earliest identifiable lesion of atherosclerosis. It has been detected in 
children as young as 10 years of age and consists of lipid-laden macrophages overlying 
lipid-laden smooth muscle cells. They occur at the same anatomic sites as subsequent 
fibrous plaques6.  
As the lesion grows, as shown in (fig 3)  it encroaches into the lumen of the vessel which 
can occlude the vessel. The plaque can also erode into the media or rupture or fissure 
which processes can allow blood to enter and disrupt the arterial wall or precipitate 
thrombosis or local vasospasm13.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3 : Atherosclerosis Time course 
 
 
 
 
 
 
A Vulnerable atherosclerotic plaque (high-risk or unstable plaque) (fig 4) is associated 
with an increased risk of disruption, distal embolization, and vascular events. Vulnerable 
plaque is an advanced histologic lesion with a large lipid core (filled with lipid and cell 
debris), a thin fibrous cap, ulceration, intraluminal thrombosis, and intraplaque 
hemorrhage, as well as intense infiltration by macrophages and other inflammatory 
cells14,15.  
 
 
 
 
 
 
 
 
 
 
 
Fig 4 : Determinants of plaque vulnerability 
 
 
 
 
 
Categories of Risk Factors for Atherosclerosis and Cardiovascular Diseases16-20 
CONVENTIONAL 
   smoking 
 Diabetes mellitus  
 Hyperlipidemia  
PREDISPOSING  
   •    Advanced age 
   •    Overweight/obesity 
   •    Physical inactivity 
   •    Gender: male sex, postmenopausal women 
   •    Insulin resistance  
   •    Family history/genetics 
   
•    Behavioral/socioeconomic factors—race 
 
CONDITIONAL  
   •    Homocysteine 
   •    C-reactive protein (high-sensitivity CRP) 
   •    Fibrinogen 
   •    Lipoprotein (a) 
   •    Hypertriglyceridemia  
EMERGING (NOVEL)  
   
•    Inflammatory markers  
   •    Serum amyloid A (SAA) 
   •    White blood cell count (WBC) 
   
•    Cytokines ( IL-1β, IL-6, IL-10, IL-18, monocyte chemotactic protein-1 
[MCP-1]  
   •    Cell adhesion molecules (ICAM-1, VCAM-1, P-selectin, etc.) 
   •    Soluble CD40 ligand (sCD40L) 
   •    Protease-activated receptors (PARs) 
   •    Erythrocyte sedimentation rate (ESR) 
   
•    Lipoprotein-associated phospholipase A2 (LP-PLA2) 
 
 
   
•    Infectious agents  
   •    Chlamydia pneumoniae, 
   •    Cytomegalovirus (CMV) 
   •    Herpes simplex virus (HSV) 1 and 2 
   •    Helicobacter pylori 
   •    Hepatitis A virus 
 
   
•    Vascular calcification markers  
   •    Osteopontin (OPN) 
   •    Osteoprotegerin (OPG) 
   •    Setuin 
 
   
•    Hemostatic factors and hypercoagulable states  
   •    Lupus anticoagulant 
   •    D-dimers 
   •    Markers of platelet activation 
   •    Tissue plasminogen activator (tPA) 
   •    Plasminogen activator inhibitor-1 (PAI-1) 
   •    Prothrombin 1 and 2 
   •    Protein Z 
 
   •    Matrix metalloproteinases 
   •    Adipokines: leptin, adiponectin 
   •    Endothelial progenitor cells 
   •    Creatinine 
   •    Urate 
   •    Microalbuminuria 
   •    Small dense low-density lipoprotein (LDL) (sdLDL) 
   
•    Oxidative stress  
   •    Oxidized LDL (ox-LDL) 
   •    Lectin-like oxidized LDL receptor-1 (LOX-1) 
   •    Myeloperoxidase 
   •    Oxidant capacity 
   •    Reactive oxygen species (ROS) 
 
   •    Miscellaneous  
   •    Alcohol 
   •    Pregnancy-associated plasma protein-A (PAPP-A) 
   •    Asymmetric dimethylarginine (ADMA) 
   
•    Heat shock proteins (HSPs) 
 
 
 
The commoner and more prevalent risk factors are discussed briefly as follows: 
Age: 
Athereosclerotic lesions increase with age21 
Sex: 
Atherosclerotic diseases have increased prevalence in men than in women. The favorable 
factors for women include higher high density lipoprotein level throughout their life, 
lower triglyceride level, less central obesity, protection due to estrogen and lower iron 
storage levels22. Diabetes Mellitus is a strong risk factor among women, nearly 
eliminating the normal protection offered by estrogen. With menopause, Low Density 
Lipoprotein level begins to rise, whereas HDL levels stop climbing or decrease slightly. 
This leads to worsening of LDL:HDL ratio. Estrogen may have direct atheroprotective 
effects on the vessel wall through estrogen receptors23. 
Family History: 
Atherosclerosis and CHD are found to run in families. It may be due to the influence of 
genetic factors as hyperlipidemia and hyperfibrinogenemia are said to be genetically 
determined. It has also been attributed to the shared family environment, particularly 
dietary and social habits21. 
Sedentary life style: 
Physical inactivity increases the risk of atherosclerosis. Regular Physical exercise is 
found to have a protective effect against atherosclerosis by increasing HDL, lowering 
blood pressure, reducing obesity, reducing blood clotting, promoting collateral vessel 
development and improving insulin sensitivity24. 
Diet: 
Diet deficient in poly unsaturated fatty acids are associated with increased risk of 
atherosclerosis. Low levels of vitamin C, vit E and other antioxidants may enhance the 
production of oxidized LDL involved in the pathogenesis of atherosclerosis21. 
Smoking: 
Tobacco smoking continues to have a devastating impact on public health and is a critical 
modifiable risk factor for atherosclerosis, including peripheral arterial disease (PAD). 
Cigarette smoking mediates its adverse cardiovascular effects through deleterious effects 
on the artery wall, particularly the endothelium, along with effects on sympathetic tone, 
metabolism, and the coagulation and fibrinolytic systems. The central components that 
lead to these adverse effects are carbon monoxide and nicotine25-29 
 
Mechanisms of Adverse Cardiovascular Effects of Cigarette Smoking 
VASCULAR INJURY  
   •    Endothelial cell damage 
   •    Increased platelet and leukocyte adhesion to endothelial cells 
   •    Impaired nitric oxide bioavailability causing abnormal vasomotor tone 
   •    Increased endothelin-1, a potent vasoconstrictor 
METABOLIC ABNORMALITIES  
   •    Increased total and LDL cholesterol 
   •    Increased triglycerides 
   •    Decreased HDL cholesterol 
   •    Insulin resistance 
HEMATORHEOLOGIC  
   •    Increased platelet aggregation 
   •    Increased fibrinogen and factor VII 
   •    Increased tissue factor expression 
   •    Impaired release of t-PA- tissue plasminogen activator 
 
•    INFLAMMATION  
   •    Source of oxidative stress 
   •    Increased inflammatory markers (C-reactive protein, WBC count) 
   •    Increased activity of MMPs- matrix metalloproteinase 
INCREASED SYMPATHETIC TONE  
   •    Increased heart rate 
   •    Increased blood pressure 
   •    Increased myocardial oxygen demand 
 
•    Peripheral vasoconstriction 
Smoking cessation rapidly and markedly reduces the risk for coronary 
atherosclerosis indicating that the responsible processes are reversible to some 
extent30.smoking has been shown to be twice as likely to cause PAD as coronary 
artery disease31. The estimated fraction of PAD attributable to smoking is as high 
as 76%32 
Alcohol: 
It is another prominent risk factor for atherosclerosis in that it affects the lipid 
profile. Though moderate alcohol intake is found to be associated with higher 
concentrations of HDL, increased apo A1 and decreased fibrinogen33, chronic 
heavy alcoholism is associated with increased triglycerides and increased risk for 
atherosclerotic complications. 
 
 Obesity: 
The central distribution of body fat is an independent risk factor for atherosclerosis in 
spite of the frequent association with other adverse effects such as hypertension, diabetes, 
and physical inactivity. Obesity has been found to promote insulin resistance, 
hyperinsulinemia, hypertension, hypertriglyceridemia, and increased LDL cholesterol 
involved in the pathology of atherosclerosis9,24. 
DIABETES MELLITUS 
DM is a strong independent risk factor for atherosclerosis increasing risk by atleast 2 
times in both sexes. The proatherogenic changes associated with diabetes may predate its 
diagnosis and include derangements in the regulation of blood flow, abnormalities in the 
components of blood vessels, and alterations in coagulation and rheology. In addition to 
increasing the burden of disease, these derangements result in the activation of 
inflammatory pathways, which increases the activity of the disease. These changes are 
associated with an increased risk for accelerated atherogenesis, as well as poor 
outcomes34. 
Endothelial cell dysfunction is key to the pathophysiology of atherosclerosis in DM. 
Several mechanisms contribute to the endothelial dysfunction, including hyperglycemia, 
free fatty acid (FFA) production, and most importantly, insulin resistance35. 
Hyperglycemia blocks the function of endothelial nitric oxide synthase (eNOS) and 
boosts the production of reactive oxygen species, which impairs the vasodilator 
homeostasis fostered by the endothelium. This oxidative stress is amplified because in 
endothelial cells, glucose transport is independent of insulin and not downregulated by 
hyperglycemia36. 
 In addition to hyperglycemia, insulin resistance plays a role in the loss of normal NO 
homeostasis. NO is a potent stimulus for vasodilatation and limits inflammation via its 
modulation of leukocyte–vascular wall interaction. Furthermore, NO inhibits vascular 
smooth muscle cell (VSMC) migration and proliferation and limits platelet activation. 
Therefore, the loss of normal NO homeostasis can result in risk for a cascade of events in 
the vasculature that lead to atherosclerosis and its consequent complications37. 
The common precipitating factors of atherosclerosis in DM are increased LDL, decreased 
HDL, high triglycerides that in turn increases triglyceride rich lipoprotein remnant 
particles. Increased small dense LDL, elevated lipoprotein(a), enhanced lipoprotein 
oxidation, glycation of LDL, increased fibrinogen, increased platelet aggregability, 
impaired fibrinolysis, plasminogen activator inhibitor-1 (PAI-1)38. 
DYSLIPIDEMIA 
The essential role of atherogenic lipoproteins in the pathogenesis of atherosclerotic 
vascular disease has been well established, as well as the benefits of lipid management 
for the primary prevention and amelioration of existing atherosclerotic vascular disease. 
Although much of the evidence on the management of lipid disorders has resulted from 
studies on atherosclerotic cardiovascular disease and, to a lesser extent, cerebrovascular 
disease, this experience is applicable to the prevention and treatment of peripheral artery 
disease (PAD) because of the common pathophysiology of atherosclerosis in any 
vascular bed1. 
The major lipids in the body are triglycerides, free cholesterol, cholesterol esters and 
phospholipids. 
Triglycerides are the storage form of fat; they serve as a source of energy and are stored 
in the adipose tissue. Cholesterol serves as a component of cell membranes and as a 
precursor for steroid hormones and bile acids. Phospholipids are the major components of 
cell membranes and lipid transporting lipoproteins. They are amphipathic 
lipids.Cholesterol and triglycerides are hydrophobic compounds and cannot dissolve in 
plasma directly, so they are carried in circulation as a complex with the amphipathic 
phospholipids and water soluble lipoproteins39. 
LIPOPROTEINS 
Lipids are chemically insoluble in the aqueous medium of blood and must be carried by 
spherical particles in which the hydrophobic lipid components are surrounded by an 
envelope of hydrophilic phospholipids and proteins known as apolipoproteins. These 
lipoprotein particles have the principal function of transporting lipids from the intestine 
and liver through the bloodstream to the various cells of the body where they can be 
stored, used for important synthetic processes, and metabolized to yield energy. The 
various apolipoproteins, such as apoB, apo A, apo E, and apo C, serve important 
functions in metabolism of the contained lipid and also are specific to the binding of 
lipoproteins to specific receptors on the surface of cells throughout the body. All 
lipoproteins are organized into a hydrophobic core of neutral lipids (triglycerides and 
cholesteryl esters) and a hydrophilic surface coat of polar lipids (free cholesterol and 
phospholipids) and apolipoprotein (fig 5 ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 5 : GENERAL STRUCTURE OF LIPOPROTEIN 
                                          
 
 
 
Although lipoprotein particles, differing in their relative lipid and lipoprotein 
composition, size, density and function, they actually form a heterogenous continuum, a 
traditional classification based on the density at which lipoproteins float during ultra 
centrifugation, divides them into the following classes40: 
 Chylomicrons  
 Very Low Density Lipoproteins 
 Intermediate Density Lipoproteins 
 Low Density Lipoproteins 
 High Density Lipoproteins 
Additionally, lipoproteins can be classified on the basis of electrophoretic mobility. In 
addition to the five lipoprotein classes, a heterogenous class of low density lipoprotein 
like lipoprotein particles termed Lipoprotein(a), containing apolipoprotein(a) and 
apolipoprotein B100 as protein moiety has been characterized. Within the classical 
lipoprotein fractions high density lipoprotein fraction has been shown to be comprised of 
several distinct subclasses, differing in their density, particle size or apolipoprotein 
composition41.  
The major characteristics of the lipoproteins have been described in the table I. 
 
 
 
 
Table I: Characteristics of the major plasma Lipoproteins 
  Composition   
Lipoprotein Source Diamete
r (nm) 
Densit
y 
(g/mL)
Protei
n (%) 
Lipi
d 
(%) 
Main Lipid 
Components 
Apolipoprotei
ns 
Chylomicron
s 
Intestine 90–1000 < 0.95 1–2 98–
99 
Triacylglycero
l 
A-I, A-II, A-
IV,1 B-48, C-I, 
C-II, C-III, E 
  
Chylomicron 
remnants 
Chylomicron
s 
45–150 < 
1.006 
6–8 92–
94 
Triacylglycero
l, 
phospholipids, 
cholesterol 
B-48, E 
VLDL Liver 
(intestine) 
30–90 0.95–
1.006 
7–10 90–
93 
Triacylglycero
l 
B-100, C-I, C-
II, C-III 
IDL VLDL 25–35 1.006–
1.019 
11 89 Triacylglycero
l, cholesterol 
B-100, E 
LDL VLDL 20–25 1.019–
1.063 
21 79 Cholesterol B-100 
HDL Liver, intes-
tine, VLDL, 
chylomicron
s 
  Phospholipids, 
cholesterol 
A-I, A-II, A-
IV, C-I, C-II, 
C-III, D,2 E 
  
HDL1 
  
  20–25 1.019–
1.063 
32 68   
HDL3 
  
  10–20 1.063–
1.125 
33 67   
HDL3 
  
  5–10 1.125–
1.210 
57 43   
Pre -
HDL3 
  
  < 5 > 
1.210 
  A-I 
Albumin/fre
e fatty acids 
Adipose 
tissue 
  > 
1.281 
99 1 Free fatty 
acids 
  
 
 
 
Importance of Non–High-Density Lipoprotein Cholesterol* 
•     Known predictor of CHD in epidemiology 
•     Equivalent to total apo B-100 and TC/HDL 
•     Represents the sum of LDL, Lp(a), IDL, and VLDL: all atherogenic apo B–
containing lipoproteins 
•     Lipid equivalent of hemoglobin A1c
CHD, coronary heart disease; HDL, high-density lipoprotein; IDL, intermediate-
density lipoprotein; Lp(a), lipoprotein (a); TC, total cholesterol; VLDL, very-low-
density lipoprotein. 
* Non–HDL cholesterol = TC − HDL cholesterol. 
Apolipoproteins : 
Apolipoproteins are specific protein components of lipoproteins. They carry out several 
roles and their distribution characterizes the lipoprotein. Measurement of these 
apolipoproteins is representative of the lipid content of the body. They maintain the 
structural integrity of the lipoprotein complex. They are responsible for the activation of 
enzymes known to be important in lipid metabolism. They facilitate uptake of 
lipoproteins by cell specific surface receptors. 
Classification and properties of major plasma lipoproteins are given in the table II. 
 
Table II : Classification and Properties of major plasma 
Apolipoproteins 
 
 
Apoliporotein Molecular weight Chromosomal 
location 
Function  Lipoprotein 
carrier 
Apo A-I 29016 11 Activates LCAT HDL 
Apo A-II 17414 1 Inhibits LPL Chylomicron 
HDL 
Apo B-100 512713 2 Secretion of 
triglyceride from 
liver binding protein 
to LDL receptor 
VLDL, IDL, LDL
Apo B-48 240800 2 Secretion of 
triglyceride from 
intestine 
Chylomicron  
Apo C-I 6630 19 Activates LCAT Chylomicron, 
VLDL, HDL 
Apo C-II 8900 19 Cofactor LPL Chylomicron, 
VLDL, HDL 
Apo C-III 8800 11 Inhibits apo C-II 
Activation of LPL 
Chylomicron, 
VLDL, HDL 
Apo E 31435 19 Facilitates uptake of 
chylomicron 
remnant and IDL 
Chylomicron, 
VLDL, HDL 
Apo (a) 187000- 662000 6 Thrombogenicity  Lp(a) 
 
 
The general characteristics of the apolipoproteins central to the pathogenesis of 
atherosclerosis are discussed here: 
Apolipoprotein A-I 
 Major protein component of HDL particles (Good Cholesterol) 
 Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is 
quickly transferred to HDL in the bloodstream. 
 The protein promotes cholesterol efflux from tissues to the liver for excretion 
 ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may 
have an anticlotting effect42 
 It is a cofactor for Lecithin Cholesterol Acyl Transferase (LCAT) enzyme 
 ApoA-1 Milano is a naturally occurring mutant of ApoA-I. Paradoxically, 
carriers of this mutation have very low HDL cholesterol levels, but no increase in 
the risk of heart disease43. 
 ApoA-I binds to lipopolysaccharide or endotoxin, and has a major role in the anti-
endotoxin function of HDL44 
 Defects in the gene encoding it are associated with HDL deficiencies, including 
Tangier disease, and with systemic non-neuropathic amyloidosis. 
Apolipoprotein B-100 : 
It is a monomeric glycoprotein of molecular weight 550 kDa. It is the most abundant 
plasma apolipoprotein and the only protein of LDL (Bad cholesterol)45 
The apo B protein occurs in the plasma in 2 main isoforms, APOB48 and APOB100. The 
first is synthesized exclusively by the small intestine, the second by the liver. Both 
isoforms are coded by APOB and by a single mRNA transcript larger than 16 kb. 
APOB48 is generated when a stop codon (UAA) at residue 2153 is created by RNA 
editing. There appears to be a trans-acting tissue-specific splicing gene that determines 
which isoform is ultimately produced. Alternatively, there is some evidence that a cis-
acting element several thousand bp upstream determines which isoform is produced.As a 
result of the RNA editing, APOB48 and APOB100 share a common N-terminal 
sequence, but APOB48 lacks APOB100's C-terminal LDL receptor binding region. Apo 
B48 is the chief apoprotein of chylomicrons. 
It consists of 4536 amino acid residues and is organized into several domains viz46. 
- Lipid binding domain 
- Receptor binding domain 
- Domains involved in lipoprotein(a) assembly 
- Lipoprotein lipase binding domain 
- Hepatic lipase binding domain 
- Microsomal triglycerides transfer protein- binding domain 
At the early stage of production of the apo B molecule, targeting of secretory proteins to 
the endoplasmic reticulum (ER) is achieved by the translation of the signal sequence and 
building of this to a signal recognition particle which recognizes a “docking Protein” on 
the ER. The signal peptide is then cleaved by a protease. So this part of this peptide 
doesnot appear in the mature circulating protein but may have an important effect on its 
rate of transport. Thus the translocation rate of the protein across to the ER is highly 
likely to be affected by the polymorphism of the gene encoding it. 
Apo B-100 I essential for the assembly and secretion of VLDL, maintenance of structural 
integrity of LDL and for the uptake of LDL by the hepatic receptors47. Structure of LDL 
with apo B100 is given in fig 6. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6 : STRUCTURE OF LDL 
 
 
 
 
 
 
 
 
 
The structure of apo B has been analyzed in terms of lipid binding, lipoprotein assembly, 
and LDL receptor pathway mediated LDL clearance. In apo B 100 few of the predicted 
alpha helices are truly amphipathic, so are the beta strands that contain alternate 
hydrophobic and hydrophilic amino acids. Lipid binding structures in the form of 
amphipathic alpha helices and beta strands and hydrophobic domains are distributed 
throughout the length of apo B-100 giving the molecule its characteristics of insolubility 
in aqueous media and non-exchangeability.  
The apo B-100 remains tightly attached to its core lipid throughout the molecule 
transition that leads to the formation of LDL, during which triglyceride and phospholipid 
are distributed to muscle and adipose tissue and all other VLDL apoproteins like apo E & 
C are lost to different lipoprotein fractions. 
Several features have been identified that may have importance in lipoprotein assembly. 
Cysteine residues determine the protein tertiary structure. Six out of seven cysteines in 
apo B-100 are involved in intramolecular disulphide linkage. The cysteine rich domain of 
apo B-100 may confer specific globular structure that is necessary for nascent lipoprotein 
assembly and transport form the ER to the Golgi apparatus. 
Apolipoprotein(a) : 
Apolipoprotein[a] is the highly glycosylated, hydrophilic apoprotein of lipoprotein[a] 
(Lp[a]). It is covalently bound to the apoB of the LDL like particle.(fig 7)  Lp(a) plasma 
concentrations are highly heritable and mainly controlled by the apolipoprotein(a) gene 
[LPA] located on chromosome 6q26-27. Apo(a) proteins vary in size due to a size 
polymorphism [KIV-2 VNTR], which is caused by a variable number of so called kringle 
IV repeats in the LPA gene. This size variation at the gene level is expressed on the 
protein level as well, resulting in apo(a) proteins with 10 to > 50 kringle IV repeats (each 
of the variable kringle IV consists of 114 amino acids)48.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7 : STRUCTURE OF Apo(a) IN LIPOPROTEIN (a) 
 
               
 
 
 
 
 
 
 
 
 
It is generally considered to be a multimeric homologue of plasminogen (kringle domain 
and a serine protease domain), and to exhibit atherogenic/thrombogenic properties. The 
kringle domain encompasses 11 distinct types of repeating units, 9 of which contain 114 
residues. These units, called kringles, are similar but not identical to each other or to 
PGK4. Apo[a] kringles are linked by serine/threonine- and proline-rich stretches similar 
to regions in immunoglobulins, adhesion molecules, glycoprotein Ib-alpha subunit, and 
kininogen49. 
The pathogenic consequences of this structural peculiarity of apo(a) are described in 
detail under Lipoprotein(a). 
Lipoprotein metabolism  
This can be divided into an exogenous and an endogenous phase50 . FIG 8. 
 
 
 
 
 
 
 
 
 
 
FIG 8 :  LIPOPROTEIN METABOLISM- EXOGENOUS AND 
ENDOGENOUS PHASES 
 
 
 
HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LCAT, lecithin-
cholesterol acyltransferase, LDL, low-density lipoprotein; VLDL, very-low-density 
lipoprotein 
 
 
 
 
 
 
Chylomicrons : 
During the exogenous phase, dietary lipids and lipids that are recirculated in bile are 
absorbed into enterocytes and packaged as very large lipoproteins called chylomicrons. 
 Although dietary cholesterol and triglycerides are absorbed by different mechanisms 
within the gastrointestinal (GI) tract, they are combined in this single chylomicron 
particle for transport from the GI tract to the rest of the body, with triglycerides 
constituting approximately 90% of the chylomicron's lipid content. These large 
lipoproteins are transported from the gut through the thoracic duct and into the 
bloodstream. Because of their very large size, when in significant concentration, 
chylomicrons account for the turbidity or “milkiness” of plasma, known as postprandial 
lipemia, seen in some individuals with a variety of metabolic and inherited disorders. 
 Chylomicrons are distinguished by the presence of one apo B-48 molecule in each 
particle. In the bloodstream, the enzyme lipoprotein lipase (LPL) hydrolyzes the 
triglyceride contained within the chylomicron into free fatty acids, which are then stored 
in adipocytes and muscle cells to be metabolized for future energy production. The 
remaining triglyceride-poor chylomicron remnant contains only the absorbed dietary 
cholesterol, which is then transported to the liver for storage. Recent studies of 
atherosclerotic lesions have found apo B-48 within plaque, thus implicating these 
chylomicron remnants as atherogenic particles. 
 
 
Very-Low-Density Lipoproteins  
The endogenous phase of lipoprotein metabolism involves the formation in the liver of 
very-low-density lipoproteins (VLDLs) containing both cholesterol and triglycerides 
derived from stores of these two lipids within the liver and adipocytes (Table 28-1). Each 
VLDL particle contains apolipoproteins from the C and E family and one molecule of 
apo B-100 per particle. As with chylomicrons, the predominant lipid component of 
VLDL is triglyceride, which accounts for approximately 70% of its lipid content. Though 
not as large as chylomicrons, VLDL is large enough to cause lipemia when present in 
very high concentration. VLDL is released from the liver into the bloodstream, where 
LPL again facilitates removal of the triglyceride component of VLDL and presents it to 
the muscle cell as fuel for energy production. Through this mechanism, stored 
triglycerides are provided to the muscle and other cells during fasting or starvation as a 
more energy-rich alternative to glucose. As the triglyceride is removed, two additional 
atherogenic lipoprotein particles are formed, VLDL remnants and intermediate-density 
lipoproteins (IDLs). These triglyceride-rich lipoprotein particles are atherogenic and play 
an important role in the accelerated atherosclerosis observed in metabolic syndrome and 
type 2 diabetes mellitus.  
Low-Density Lipoprotein 
In addition to LPL, another lipase known as hepatic lipase participates in the conversion 
of VLDL to LDL, the most atherogenic of all lipoprotein particles. Although a number of 
other apolipoproteins were attached to the original VLDL particle, only one apo B-100 is 
present in each LDL particle. 
 LDL binds to specific LDL receptors on the surface of each cell, and such binding 
facilitates transfer of the remaining cholesterol to these cells, where it can be stored for 
future use to make such chemical products as cell membranes, steroid hormones, and bile 
acids. The circulating LDL concentration in plasma is determined by the number of LDL 
receptors on the various cells of the body, with the liver accounting for more than 70% of 
this total receptor number. In turn, the number of LDL receptors is regulated by the 
intracellular concentration of cholesterol within each cell. When the intracellular 
cholesterol content of the cells is low, LDL receptor synthesis is upregulated, receptor 
numbers increase, and the LDL concentration of circulating plasma diminishes. On the 
other hand, when intracellular cholesterol is increased, LDL receptor synthesis is 
downregulated, receptor numbers diminish, and LDL within the circulation rises. When 
plasma LDL is present in excess, atherosclerosis results in proportion to the degree of 
circulating LDL. Humans are born with a maximum number of LDL receptors and a very 
low circulating LDL level of 25 to 30 mg/dL (0.65 to 0.78 mmol/L). Over our lifetime, 
the current lifestyle of excessive calorie, cholesterol, and saturated fat intake and 
inactivity results in an increasing intracellular cholesterol level, downregulation of LDL 
receptors, and attainment of the currently observed excess LDL cholesterol levels that has 
resulted in the epidemic of atherosclerosis seen throughout the world.  
High-Density Lipoproteins  
HDL is synthesized by the liver and intestine as apo A-I, which is then released into the 
bloodstream as a lipid-poor discoid particle. As it circulates, stored cholesterol is released 
from peripheral cells through the action of a specific transporter known as ABCA1 
cassette transporter.  As cholesterol is absorbed by the discoid apo A-I and converted to 
cholesterol ester under the influence of lecithin-cholesterol acyltransferase (LCAT), HDL 
becomes a spherical particle. Additional cellular cholesterol is then added by another 
cassette transporter, ABCG1, and through the action of the receptor SR-B1. The HDL 
particle can then return to the liver, where it binds to hepatic SR-B1 and releases its 
cholesterol, or it can exchange a portion of its cholesterol content for triglyceride from 
VLDL through the chemical action of the cholesterol ester transfer protein (CETP). The 
exchanged cholesterol can then be transported back to the liver by LDL. This process is 
known as “reverse cholesterol transport” and plays an important role in the 
antiatherogenic properties of the HDL particle51. FIG 9. 
 
 
 
 
 
 
 
 
 
FIG 9 : REVERSE CHOLESTEROL TRANSPORT OF HDL 
                                                  
 
ABCA1, adenosine-binding cassette transporter 1; CETP, cholesterol ester transfer 
protein; HDL, high-density lipoprotein; LCAT, lecithin-cholesterol acyltransferase; LDL, 
low-density lipoprotein; LDLR, LDL receptor; SR-B1, scavenger receptor type B1; 
VLDL, very-low-density lipoprotein 
 
Table III : ATP III Guidelines for the Evaluation of Fasting Lipid 
Profile 
 
  Conventional Units(mg/dL) SI units (mmol/L) 
Low-Density Lipoprotein Cholesterol 
Optimal <100 <2.59 
Near optimal 100-129 2.59-3.34 
Borderline high 130-159 3.37-4.12 
High 160-189 4.14-4.90 
Very high >190 >4.92 
High-Density Lipoprotein Cholesterol 
Low <40 <1.04 
High >60 >1.55 
Triglycerides   
Normal <150 <1.70 
Borderline 150-199 1.70-2.25 
High 200-499 2.26-5.64 
Very high >500 >5.65 
 
 
 
 
 
 
 
Hence the endogenous lipid transport system can be divided into two subsystems: 
 Apo A-I lipoprotein system (high density lipoprotein) 
 Apo B-100 lipoprotein system (VLDL, IDL, LDL) 
Apo A-I lipoprotein system: 
HDL particles are the main mediators of the reverse cholesterol transport system whereby 
cholesterol synthesized or deposited in peripheral cells is returned to liver52. 
This process begins with the removal of free cholesterol from the cel membranes to 
nascent HDL particles secreted by the liver and intestine, and esterification of free 
cholesterol by lecithin cholesterol acyl transferase after which the cholesteryl ester I 
stransferred to the hydrophobic core of the HDL particle53. In this process nascent HDL 
is converted to spherical lipid- rich HDL. Part of the HDL core cholesteryl ester is then 
transferred to apolipoprotein B-48 or apolipoprotein B-100 containing lipoproteins in 
exchange for triglycerides by the cholesteryl ester transfer protein (CETP). The 
cholesteryl esters remaining in the HDL particles are taken up by the hepatocytes either 
via receptor- mediated endocytosis of apolipoprotein E containing HDL particles by the 
remnant receptor or through selective removal of HDL cholesteryl ester by the hepatic 
HDL receptor. At the same time triglycerides transferred from the other lipoproteins to 
HDL are hydrolyzed by hepatic lipase, leading to the conversion of triglycerides – rich 
HDL2 to triglycerides poor HDL3 particles, and the release of free apolipoprotein A-1 and 
lipid poor HDL to be reused in the reverse cholesterol transport cycle. Besides the 
exchange of cholesteryl ester for triglycerides, the complex interplay of HDL with other 
lipoproteins during reverse cholesterol transport involves exchange of other components 
as well, such as apolipoproteins and phospholipids54. 
Apo B-100 lipoprotein system: 
The apolipoprotein B-100 system begins with the hepatic assembly and secretion of apo 
B-100 containing VLDL particles. Therafter VLDL- triglycerides are hydrolyzed in 
peripheral tissues by lipoprotein lipase (LPL) and the particles are converted to smaller 
triglyceride depleted intermediate density lipoprotein (IDL)55. The liver via the LDL 
receptor conceivably removes some of the IDL particles. The rest are converted to LDL 
particles. 
The liver through the LDL  receptor clears most of the LDL particles. Other receptors and 
non-receptor mediated uptake through still poorly defined pathways play a smaller role in 
LDL clearance56. Concentration of LDL considerably varies within population. 
Lipoprotein(a): 
Lipoprotein Lp(a) is a major and independent genetic risk factor for atherosclerosis and 
cardiovascular disease. The essential difference between Lp(a) and low density 
lipoproteins (LDL) is apolipoprotein apo(a), a glycoprotein structurally similar to 
plasminogen, the precursor of plasmin, the fibrinolytic enzyme57. Lp(a), is an LDL-like 
particle discovered by Berg in 1963.  
Lp(a) is a complex particle composed of a lipid core and two disulfide-linked subunits: 
apolipoprotein B-100 and apolipoprotein apo(a). The lipid core and apo B-100 of Lp(a) 
are shared with LDL; in contrast, the apo(a) glycoprotein confers its characteristic 
properties on Lp(a). Apo(a) shows a high degree of homology with plasminogen, the 
precursor of the fibrinolytic enzyme plasmin. FIG 10. 
 FIG 10 :  STRUCTURE OF LIPOPROTEIN(a) 
 
 
                               
    
 
 
 
 
 
 
 
The fact that Lp(a) has both LDL and plasminogen-like moieties suggests that Lp(a) may 
constitute a link between the processes of atherosclerosis and thrombosis. Lp(a) and 
fibrin have been identified in atherosclerotic plaques58.  
Plasminogen and apolipoprotein(a) are homologous proteins with opposite effects. FIG 
11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIG 11 :  STRUCTURAL HOMOLOGY OF APO(a) WITH PLASMINOGEN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasminogen is a single-chain glycoprotein of Mr 93,000 secreted by the liver and found 
in plasma at a concentration of 1.5 to 2 μmol/l. It consists of 791 amino acid residues 
arranged in two types of domains with functional autonomy: the kringle modules and the 
serine-proteinase region. Kringles are sequences of 80-90 amino acids arranged in a 
triple-loop tertiary structure rigidly stabilized by three disulfide bridges. The kringle 
structure was first described in prothrombin and is found in several copies in proteins that 
evolved from a common ancestral gene, i.e., plasminogen, apo(a) and hepatocyte growth 
factors59.  The kringle domains of plasminogen, designated 1 to 5, differ from each other 
and are connected to the proteinase domain by a sequence adjacent to the activation 
cleavage site Arg561-Val562. The serine-proteinase domain contains the active catalytic 
center (Ser741, His603, Asp646) and is located in the carboxy-terminal region (Val562-
Asn791), whereas the amino-terminal region (Glu1-Arg561) bears the five kringle 
domains and an amino-terminal peptide of 77 residues (Glu1-Lys77) that may be released 
by plasmin. Thus, native plasminogen possesses a glutamic acid as the amino-terminal 
residue (Glu-plasminogen), while the corresponding residue in the plasmin-cleaved form 
is lysine (Lys-plasminogen). Lys-plasminogen is not normally found in human plasma.  
Kringles 1 and 4 of plasminogen contain a functional subsite supported primarily by 
amino acid residues of the inner loop. Since this subsite binds to lysine residues of fibrin 
and cell membrane proteins it has been termed lysine-binding site or LBS. The structure 
of this subsite, an ionic dipole with the anionic and cationic sites positioned at opposite 
ends of a hydrophobic trough, has been well defined. In both kringle 1 and kringle 4, the 
anionic center is constituted by Asp55 and Asp57 while the cationic center is mainly 
represented by Arg34 and Arg71 in kringle 1, and by Lys35 and Arg71 in kringle 460. 
The specific interactions between lysine residues in fibrin or cell membrane proteins and 
the lysine-binding subsites in kringles 1 and 4 of plasminogen allow plasminogen binding 
and activation. 
Apo(a) contains a variable number of kringle domains that share 61-75% homology with 
kringle 4 of plasminogen. The kringle 4-like repeats of apo(a) are followed by a single 
copy of plasminogen kringle 5 and a protease domain that shares 94% homology with the 
corresponding domain of plasminogen61. Kringle 4 copies of plasminogen in apo(a) are 
similar but not identical and have been classified into 10 different types. Kringle 4 type 2 
presents the lowest degree of homology with plasminogen kringle 4 and has no functional 
LBS; the number of this type of kringle in apo(a) is variable and gives rise to a series of 
apo(a) isoforms that contribute to the heterogeneity of Lp(a): a total of 34 apo(a) alleles 
and glycoproteins with molecular masses ranging  from ~300 to ~800 kDa have been 
identified by protein (13) and cDNA (14) analysis. The other nine kringle types are 
present as single copies in all isoforms; kringle 4 type 9 possesses an additional cysteine 
residue that ensures the covalent binding between apo(a) and apo B-100 and thereby the 
formation of the Lp(a) particle62. 
Sequence comparison and molecular modeling have shown that a lysine-binding pocket 
similar to that of plasminogen kringle 4 is present in kringle 4 type 10 of apo(a) and that 
slightly modified LBS are present in kringle 4 types 5 to 8  these kringle copies may 
confer binding capabilities similar to those of plasminogen on apo(a)63. However, the 
Arg-Val residues of the activation cleavage site in plasminogen have been replaced by 
Ser-Ile in apo(a), a substitution that impairs recognition of apo(a) by plasminogen 
activators. 
Thus, binding of apo(a) instead of plasminogen to fibrin and cell surfaces may result in a 
diametrically opposed effect, i.e.,inhibition of the generation of plasmin. 
Inhibition of the generation of plasmin is the major mechanism of action of Lp(a). FIG 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 12 : LIPOPROTEIN(a) INHIBITS FIBRINOLYSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial limited degradation of the surface of fibrin by plasmin unveils carboxy-terminal 
lysine residues and increases the local concentration of plasminogen, a process that 
amplifies and accelerates the degradation of fibrin. In a plasma milieu, the progression of 
such a process is markedly influenced by a2-antiplasmin, the specific plasmin inhibitor, 
which limits the number of carboxy-terminal lysine residues and thereby the amount of 
bound plasminogen64. Since the kringle domains behave as autonomous functional 
structures, the presence in apo(a) of kringle modules structurally related to those of 
plasminogen may result in analogous interactions with lysine residues of fibrin and cell 
membranes.  
Thus, Lp(a) interferes with the evolution of fibrinolysis on the surface of fibrin, 
endothelial cells, monocytes and platelets through binding of apo(a), an eternal zymogen 
that decreases the local concentration of plasminogen and cannot be transformed into an 
active enzyme65.  
Effects of Lp(a) such as persistence of fibrin deposits, accumulation of cholesterol and 
proliferation of smooth muscle cells in the intima are related to a decrease in plasmin 
activity. Hypofibrinolysis and cholesterol accumulation are a direct consequence of the 
presence of Lp(a) on the surface of fibrin and cell membranes: apo(a) inhibits plasmin 
formation and the LDL components favor cholesterol accumulation. FIG 13. 
 
 
 
 
 
 FIG 13 : ATHEROTHROMBOGENESIS BY LIPOPROTEIN(a) 
 
 
 
                               
 
 
 
 
 
 
 
Growth and proliferation of vascular smooth muscle cells are inhibited by active TGF-ß, 
a growth factor secreted in latent form and activated by plasmin 66. It has been recently 
shown that Lp(a) inhibits the generation of TGF-ß 67 and that the generation of plasmin 
and thereby the activation of TGF-ß are decreased in transgenic mice expressing human 
apo(a) 68. Insufficient activation of TGF-ß may result in migration and proliferation of 
smooth muscle cells into the intima, an important mechanism in atheroma plaque 
formation. FIG 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 14 :  ATHEROMA FORMATION BY LIPOPROTEIN(a) 
 
 
            
 
 
 
 
 
 
 
 
 
 
 
Modification of protein synthesis:  Lp(a) may stimulate the expression of PAI-1 and 
inhibit the synthesis of t-PA by endothelial cells in culture 69. Thus, inhibition of t-PA by 
PAI-1 and low t-PA antigen levels may enhance Lp(a)-dependent hypofibrinolysis by 
decreasing the amount of t-PA available for the activation of plasminogen. 
Binding of Lp(a) to extracellular matrix components:  Lp(a) and recombinant apo(a) 
display high affinity for fibronectin and that Lp(a) may form complexes with 
proteoglycans or glycosaminoglycans of the extracellular matrix 70. These interactions are 
not related to the lysine-binding function of kringle 4 and may contribute to the 
accumulation of Lp(a) in the vascular wall. 
Oxidation of Lp(a):  The Lp(a) and LDL particles are sensitive to oxidative processes. 
Phagocytosis of oxidized Lp(a) and LDL particles results in the formation of foam cells 
71. 
Genetic polymorphism and functional heterogeneity of Lp(a): The circulating 
concentration of Lp(a) is mainly regulated by the apo(a) gene 72. FIG 15.  The size of 
each allele varies as a function of the number of repetitive sequences encoding kringle 4 
type 2. In general, the smaller this hypervariable region and therefore the size of the 
apo(a) isoform, the higher the plasma concentration of Lp(a).  
 
 
 
 
 
 
 FIG 15 :  GENETIC DETERMINATION OF LIPOPROTEIN(a) FUNCTION 
 
 
 
 
         
 
 
 
 
 
HYPERTENSION AND ATHEROSCLEROSIS 
The pathologic influence of hypertension on the development of atherosclerosis is 
complex, the genetic makeup of the individual, behavioral tendencies (e.g., smoking), 
and environmental influences all shape the risk for development of atherosclerotic 
plaque. mouse models of hypertension exhibit increased atherosclerotic lesion size, 
although there are some exceptions.73 In addition, there are several reports of reduction in 
blood pressure resulting in reduced atherosclerosis. 
Hypertension and hypercholesterolemia interact strongly in promotion of atherosclerosis. 
The principal components of blood pressure consist of a steady component (mean arterial 
pressure) and a pulsatile component (pulse pressure). As large artery stiffness increases in 
middle aged and elderly subjects, systolic pressure rises and diastolic pressure falls 
(isolated systolic hypertension) with a resulting increase in pulse pressure74. 
One of the strongest correlations between blood pressure and atherosclerosis is 
perturbations in the renin-angiotensin system. This hormonal system is responsible for 
homeostatic control of arterial pressure, tissue perfusion, and extracellular volume. The 
juxtaglomerular cells located in each nephron produce renin, which converts 
angiotensinogen (produced mainly in the liver) to angiotensin I. Angiotensin-converting 
enzyme (ACE) converts angiotensin I to angiotensin II, which is a potent vasoconstrictor 
and mediator of aldosterone secretion.  
Studies of hyperlipidemic mice in which angiotensin II was chronically infused showed 
promotion of atherosclerosis independent of changes in arterial blood pressure75.  
Endothelial dysfunction occurs early in the atherosclerotic process, and hypertension is 
associated with endothelial dysfunction in the coronary, renal, and peripheral 
circulations. Studies in animals and humans using an agonist-induced vasodilator 
response show that this response is blunted in the setting of hypertension.76 
 One key molecule that is partially responsible for the vasodilator response and is 
involved in maintaining normal endothelial function is nitric oxide (NO). A reduction in 
endothelial-derived NO may result in not only a reduced vasodilator response but also a 
proinflammatory, prothrombotic, and procoagulant phenotype77.  
Renal artery stenosis is most commonly due to atherosclerotic disease and may lead to 
renovascular hypertension. The consequence of the reduction in blood flow to the kidney 
is activation of the renin-angiotensin-aldosterone system and possibly ischemic 
nephropathy. One proposed hypothesis is that some of the humoral factors activated by 
renal artery stenosis may accelerate the atherosclerotic process.78 Experimental studies of 
pigs with hypertension secondary to renal artery stenosis showed that increased oxidative 
stress resulted from this condition and was a stimulus for atherosclerosis independent of 
cholesterol levels.79 
 
HOMOCYSTEINE AND ATHEROSCLEROSIS 
It is a metabolic product of amino acid methionine and is found to have a direct effect on 
the vascular endothelium because it facilitates the formation of oxidized LDL which 
promotes atherogenesis. It is also said to be thrombotic and to increase collagen 
production in the extracellular matrix and promotion of smooth muscle cell growth80. 
 Prothrombotic effects of homocysteine  have been described such as down regulation of 
thrombomodulin on endothelial cells81 and upregulation of tissue factor on both 
endothelial cells and macrophages82. Studies have shown relation between 
hyperhomocysteinemia and premature disease in coronary, cerebral, and peripheral 
arteries. It may also enhance the development of atherosclerotic plaques by the following 
processes: 
 Generation of superoxide/ H2O2 (damage endothelium) 
 Enhance blood coagulation (directly activate platelet aggregation) 
 Inhibiting dilation of small arteries (increased vulnerability to clot/ plaque) 
 Promote arterial smooth muscle cell proliferation 
 It may interact with LDL to form LDL-Homocysteine-thiolactone aggregates, 
which are taken up by the macrophages, incorporated into foam cells, and become 
early atherosclerotic plaques. 
Daily supplementation of folic acid, vitamin B6, vitamin B12, lower serum homocysteine 
concentrations and has been reported to decrease plaque area of patients. Women who 
took maximal levels of these agents had half the risk of having a myocardial infarction 
compared to those with the lowest intake82 
HEMOSTATIC FACTORS 
Several systemic haemostatic factors including fibrinogen, factor VII, Plasminogen 
Activator Inhibitor-I, Tissue Plasminogen activator and platelets have been identified as 
determinants of future coronary heart events83. The most powerful and most consistent 
predictor coronary heart disease among the haemostatic factors- fibrinogen is strongly 
related to smoking, diabetes and C- reactive protein (an acute phase reactant like 
fibrinogen) all of which are strong consistent, and independent predictors of coronary 
heart disease84 
 
CYTOKINES AND ATHEROSCLEROSIS 
Atherosclerosis is a chronic disease of the arterial wall where both innate and adaptive 
immunoinflammatory mechanisms are involved. Inflammation is central to all stages of 
atherosclerosis85. 
Cytokines are defined as  a group of protein cell regulators, variously called 
lymphokines, monokines, interleukins, interferons ( “chemokines”), which are produced 
by a wide variety of cells in the body, play an important role in many physiological 
responses, are involved in the pathophysiology of a range of diseases, and have 
therapeutic potential86. 
The cytokines consist of more than 50 secreted factors involved in intercellular 
communication, which regulate fundamental biological processes including body growth, 
lactation, adiposity, and  hematopoiesis87. Cytokines are clustered into several classes: 
interleukins, tumor necrosis factors (TNF), interferons (IFN), colony stimulating factors 
(CSF), transforming growth factors (TGF), and chemokines. They are especially 
important for regulating inflammatory and immune responses and have crucial functions 
in controlling both innate and adaptive immunity. 
The predominant actors in adaptive immunity, helper- T (Th) cells, have been categorized 
on the basis of the pattern of cytokines that they can secrete, resulting in either a cell-
mediated immune response (Th1) associated with IL-2 and IFN-γ secretion, or a humoral 
immune response (Th2), associated with IL-4, IL-5, IL-10, and IL-13 secretion. 
The classification of cytokines is given in the table-IV 
 
 
 
TABLE IV : CLASSIFICATION OF CYTOKINES 
 
 
 
Cytokines are categorized according to the structural homology of their receptors as class 
I or class II cytokines 88 . Most ILs, CSFs, and IFNs belong to one of these two classes of 
cytokines, which mediate their effects through the Janus kinase-signal transducers and 
activators of transcription (JAK-STAT) pathway.  
Three other major cytokine families encompass the IL-1 family (including IL-1α, IL-1β, 
IL-1ra, and IL-18), TNF family, and TGF-β superfamily . IL-1 and TNF family members 
activate the nuclear factor-κB (NF-κB) and mitogen activated protein (MAP) kinase 
signaling pathways, while TGF-β superfamily members activate signaling proteins from 
the smad family. 
Table –V  shows the list of pro and anti atherogenic cytokines, IL-1 and TGF beta 
deserve special mention as the chief anti atherogenic cytokines. 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE V : PRO ATHEROGENIC AND ANTI ATHEROGENIC CYTOKINES 
 
                    
 
 
 
 
 
 
 
 
 
Biological Effects of Cytokines 
 Effects on endothelial permeability89 
 Activation of adhesion molecule expression90 
 Induction of chemokine release91 
 Modulation of scavenger receptor expression92 
 Modulation of lipid metabolism93 
 Activation of 15-lipoxygenase expression in cultured macrophages94 
 Effect SMC migration/ proliferation95 
 Regulation of immune response (Th1/Th2/Treg)96 
 Conversion of CD4+ naïve cells to active CD4+ regulatory cells97 
 Oxidation of LDL (induction of cell oxidative stress)98 
 Stimulation of MMP expression99 
 Modulation of extracellular matrix expression100 
 Modulation of endothelial SMC progenitor differentiation101 
 Regulation of neo vessel formation102 
 Promotion of intra plaque neovascularization103 
 Induction of apoptosis104 
 Stimulation of micro particle release105 
 Modulation of endothelial pro coagulant activity106 
 Modulation of fibrinolysis (PAI-1)107 
Fig 16 shows the principal signaling pathways involved in atherogenesis .  
 
FIG 16: PRINCIPAL SIGNALING PATHWAYS  INVOLVED IN 
ATHEROGENESIS 
 
 
 
 
 
 
 
 
 
 
 
Pro inflammatory cytokines (IL-1, IL-18) and pathogens (known as pathogen associated 
molecular patterns PAMPs) and non pathogen activators of TLR, act through distinct 
signaling pathways that converge on the activation of NF-κB. MyD88 functions as an 
adapter molecule between the receptors of TLR or IL-1 R and downstream signaling 
kinases. Following association of MyD88 with IL-1-associated kinase IRAK-4, IRAK-4 
is autophosphorylated, dissociates from the receptor complex, and interacts with TNF-
receptor-associated factor-6 (TRAF-6), which also mediates CD40 signaling. Once 
activated, TRAF6 associates with the MAP3 kinase TAK1 108. From TAK1, two 
signaling pathways diverge; one ultimately leads to NF-κB activation and the other to 
MAP kinase activation. In its inactive form, NF-κB is bound to inhibitor of κB (IK-
κBα/β) in the cytoplasm and consists of an IκB kinase (IKK) complex containing two 
kinases IKKα and IKKβ, and the regulatory protein IKKγ (also named NEMO); IKK 
activation initiates IκBα/β phosphorylation. Phosphorylated IκB is then ubiquitinated, 
leading to its degradation by the 26S proteasome. This releases NF-κB dimers from the 
cytoplasmic NF-κB-IκB complex, allowing them to translocate to the nucleus. JNK 
phosphorylation is mediated by two MAPK kinases (MAPKKs), MKK4 and MKK7, that 
they can cooperatively activate JNK. Both kinases are required for full activation of JNK 
by environmental stressors, and MKK7 is essential for JNK activation by TNR 
engagement. Tyrosine phosphorylation activates the cytosolic inactive STATs, resulting 
in their nuclear translocation and gene activation. This pathway was originally found to 
be activated by IFNs, but a number of cytokines, growth factors, and hormonal factors 
also activate JAK and/or STAT proteins. IFN-γ utilizes JAK1 and JAK2, and usually 
activates STAT1. TGF-β-triggered signals are transduced by proteins belonging to the 
Smad (for vertebrate homologs of Sma and Mad) family. The type I receptor recognizes 
and phosphorylates Smad2 and Smad3, which associates with Smad4, forming complexes 
that participate in DNA binding and recruitment of transcription factors. Smad3 may also 
have antagonistic properties, as it plays a critical role in TGF-β-dependent repression of 
vascular inflammation by inhibiting AP-1 activity. Smad7 inhibits Smad2 and Smad3 
phosphorylation. 
 
Fig17 shows cross talks between pro atherogenic and anti atherogenic signal 
transduction pathways 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 17 : Cross talks between pro atherogenic and anti atherogenic 
signal transduction pathways 
 
 
 
 
 
 
 
Inhibitory Smads such as Smad7 downstream of IFN-γ signaling associate with activated 
receptors and interfere with Smad2 and Smad3 binding. It is noteworthy that like IFN-γ, 
the anti-inflammatory cytokine IL-10 also activates JAK and/or STAT proteins. 
However, the IL-10/IL-10R interaction activates JAK1 and Tyk2, leading to STAT3 and 
SOCS3 activation, which is central for the anti-inflammatory responses of IL-10 in 
macrophages. The inflammasome may be a central link between apoptosis and 
inflammation in pathological conditions. NF-κB may have a dual role in atherosclerosis, 
being proatherogenic through its proinflammatory properties, and antiatherogenic 
through its antiapoptotic activities. 
 
Table VI shows primary and secondary triggers for the release of cytokines in 
atherosclerosis 
 
 
 
 
 
 
 
 
 
 
 
TABLE VI : PRIMARY AND SECONDARY TRIGGERS FOR CYTOKINE 
RELEASE IN ATHEROSCLEROSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig18  shows the cytokines involved in atherosclerosis 
FIG 18 :  CYTOKINES INVOLVED IN ATHEROSCLEROSIS 
 
 
 
 
 
 
 
 
 
 
Cytokines are produced by several cell types, including inflammatory and vascular cells, 
as well as adipocytes. IL-12 and IL-18 produced by macrophages are potent inducers of 
IFN-γ and promote the differentiation of naive T cells into proatherogenic Th1 cells. 
Macrophage or macrophage-derived cytokines also activate smooth muscle cells (SMC) 
and endothelial cells (EC) to produce an array of proinflammatory mediators. On the 
other hand, the anti-inflammatory cytokines IL-10 and TGF-β, also produced by 
macrophages, promote antiatherogenic Treg cell differentiation. Other anti-inflammatory 
mediators with potent antiatherogenic properties include IL-1 receptor antagonist (IL-1ra) 
and IL-18 binding protein (IL-18BP). Interestingly, IL-4, the prototype of Th2 cells, has 
proinflammatory properties on EC. Adipocytes produce both pro- and anti-inflammatory 
mediators. Leptin activates Th1 cells but inhibits Treg cell function. Adiponectin has 
been shown to dampen macrophage activation. 
 
 
Fig 19 shows Development and maintenance of pathogenic and regulatory immunity 
in atherosclerosis 
 
 
 
 
 
 
 
FIG 19 : Development and maintenance of pathogenic and regulatory 
Immunity in atherosclerosis 
 
 
 
 
 
 
 
 
 
Candidate antigens [oxidized lipoproteins (oxLDL), heat shock proteins (HSP), 
phosphorylcholine (PC), apoptotic bodies may induce Th1, Th2, or both Th1 and Th2 
pathogenic responses. Maturation of the antigen presenting cell (APC) is necessary for T-
cell priming. The CD40/CD40L pathway is critical for Th1 differentiation. IL-6 and IL-
13 contribute to the induction of Th2 cell type. Both IFN-γ (Th1) and IL-4 (Th2) have 
been shown to promote atherogenesis. Production of IL-5 by Th2 cells is important for 
protective antibody production by B lymphocytes in response to immunization with 
oxLDL. Distinct subsets of APCs, called “tolerogenic” cells, induce the differentiation of 
the regulatory T-cell subset (Treg). The development of CD4+CD25+Foxp3+ Treg cells 
occurs in the thymus and requires TCR and CD28 engagement among other yet unknown 
factors. Interestingly, production of IL-2 by pathogenic Th1 cells is essential for the 
survival and maintenance of this Treg subset in the periphery. Other Treg cells of the Tr1 
type may not express Foxp3 and are mainly induced in the periphery in response to 
antigen stimulation. Both types of Treg cells use IL-10 and/or TGF-β to suppress the 
proliferation of pathogenic T cells in vivo. IL-6, produced in response to TLR 
stimulation, may contribute to the inhibition of Treg function. 
 
FIG. 20 shows Local and systemic effects of pathogenic and regulatory cells in 
atherosclerosis. 
 
 
 
 
FIG 20 : Local and systemic effects of pathogenic and regulatory cells in 
atherosclerosis. 
 
 
 
 
 
 
 
 
 
 
Lymphoid organs are specialized in antigen presentation and may be the major site of 
pathogenic or tolerogenic antigen presentation and T-cell priming in atherosclerosis. 
Antigen presentation may also occur within the atherosclerotic plaque, which is rich in 
cells with antigen-presenting capacity (macrophages and dendritic cells). Continuous 
trafficking of immune cells between the inflammed atherosclerotic artery and the 
lymphoid organs may be necessary to mount an adaptive immune response. CD28 
engagement and IL-2 production by pathogenic T cells are required for Treg cell survival 
and maintenance in the periphery. Treg cells suppress the pathogenic response through 
IL-10, TGF-β, and/or cell-cell contact-dependent mechanisms. The precise mechanisms 
that drive a pathogenic or a regulatory immune response in atherosclerosis are currently 
unknown. 
TRANSFORMING GROWTH FACTOR- β: 
TGF-β is a secreted protein that exists in at least three isoforms called TGF-β1, TGF-β2 
and TGF-β3. the transforming growth factor beta superfamily, includes inhibins, activin, 
anti-müllerian hormone, bone morphogenetic protein. 
Structure: TGF-β1 contains 390 amino acids and TGF-β2 and TGF-β3 each contain 412 
amino acids. They each have an N-terminal signal peptide of 20-30 amino acids that they 
require for secretion from a cell, a pro-region (called latency associated peptide or LAP), 
and a 112-114 amino acid c‐  terminal  region that becomes the mature TGF-β molecule 
following its release from the pro-region by proteolytic cleavage. The mature TGF-β 
protein dimerizes to produce a 25 KDa active molecule with many conserved structural 
motifs. TGF-β has nine cysteine residues that are conserved among its family; eight form 
disulphide bonds within the molecule to create a cysteine knot structure characteristic of 
the TGF-β superfamily while the ninth cysteine forms a bond with the ninth cysteine of 
another TGF-β molecule to produce the dimer.  
FIG 21. shows the synthesis of mature TGF beta. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 21 :  SYNTHESIS OF MATURE TGF β 
 
 
 
LAP- Latency Associated Peptide 
LTBP- Latent TGF beta Binding Protein 
 
 
 
 
 
TGF-β is a potent anti-inflammatory, immunosuppressive and pro-fibrotic cytokine, with 
major effects on the biology of SMC 109. TGF-β1- deficient mice die in utero or in the 
perinatal period because of widespread uncontrolled inflammation 110. The anti-
inflammatory and profibrotic properties of TGF-β are highly suggestive of a potential 
antiatherogenic role for this cytokine. Indeed, serum active TGF-β is markedly depressed 
in patients with advanced atherosclerosis 111, and that TGF-β1 heterozygous mice fed a 
cholate-supplemented atherogenic diet displayed increased endothelial activation and 
macrophage infiltration in the aortic sinus 112. The critical role of TGF-β for SMC matrix 
production and Plaque stability in atherosclerosis was thereafter demonstrated by studies 
using apoE_/_ mice.  Treatment of apoE_/_ mice with neutralizing antibodies to TGF-β1, 
TGF-β2, and TGF-β3 accelerates the development of atherosclerosis, with lesions 
displaying increased inflammatory cells and decreased collagen content 113. TGF-β may 
therefore reduce inflammation but also contributes to matrix production within lesions. In 
agreement with this hypothesis, treatment of apoE_/_ mice with a soluble TGF-β-
receptor II protein (TGF-RII:Fc) that inhibits TGF-β signaling resulted in larger plaques, 
with an increased frequency of macrophages and T cells and decreased collagen content 
in the atherosclerotic lesions 114. Moreover, intraplaque hemorrhages were frequently 
observed. specific inhibition of TGF-β signaling in T cells leads to the development of 
atherosclerotic Plaques with a phenotype that may potentially increase plaque 
vulnerability to rupture, strongly suggesting an important protective role of endogenous 
T-cell TGF-β  activity against vulnerability to atherosclerosis115. Bone marrow 
transplantation from transgenic mice that express a dominant negative TGF-β receptor 
type II under a T-cell-specific promoter into LDLr_/_ mice resulted in increased 
differentiation of spleen-derived T cells toward both Th1 and Th2 phenotypes 116. 
Moreover, atherosclerotic plaques of these mice showed increased T-cell infiltration and 
expression of MHC class II, along with a decrease in SMC and collagen content. 
Consistent with these findings, apoE_/_ mice with disrupted TGF-β signaling in T cells 
exhibited markedly larger atherosclerotic lesions, with a _100-fold increase in aortic IFN-
γ expression compared with apoE_/_ Littermates 115. The important role of T-cell-TGF-β 
signaling in atherosclerosis suggests that regulatory pathways in adaptive immunity are 
essential in modulation of the development and progression of the disease. 
TGF beta functions are exerted through the smad pathway. Fig 22.  TGF-β dimers bind to 
a type II receptor which recruits and phosphorylates a type I receptor. The type I receptor 
then recruits and phosphorylates a receptor regulated SMAD (R-SMAD). SMAD3, an R-
SMAD, has been implicated in inducing apoptosis. The R-SMAD then binds to the 
common SMAD (coSMAD) SMAD4 and forms a heterodimeric complex. This complex 
then enters the cell nucleus where it acts as a transcription factor for various genes, 
including those to activate the mitogen-activated protein kinase 8 pathway, which triggers 
apoptosis. 
 
 
 
 
Fig 22: TGF β – Structure, Latency, Activation and Receptor 
 
 
 
LAP - latency-associated peptide 
 LTBP- latent TGF-beta binding protein 
 M6P/IGFII-R- mannose-6-phosphate/type II insulin-like growth factor receptor 
 PLg- plasminogen  
PL- plasmin  
Smad TGF-beta signal transduction proteins 
 Anti-Smad- antagonistic Smad 
 Co-Smad- common-partner Smad 
 R-Smad- receptor-regulated Smad 
 TGase- transglutaminase 
 TbetaR-I, -II, -III- TGF-beta receptor type I, II, III 
 TSP- thrombospondin 
 uPA- urokinase plasminogen activator 
 uPA-R- uPA receptor.  
 
 Salient Functions : 
 TGF beta plays a crucial role in the regulation of cell cycle at G1 phase 
 Regulates the immune system through the Foxp3+ regulatory T cells. 
 Inhibits the activation of lymphocytes and monocyte derived phagocytes 
 Vital role in cancer, heart disease, renal disease, hypertension, inflammation, 
connective tissue diseases like Marfan syndrome, etc. 
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AIM OF THE STUDY 
Atherosclerosis is a multifactorial disease, the cornerstone being dyslipidemia and 
oxidative stress. Cardiovascular manifestations of atherosclerosis has been extensively 
studied, and treatment of dyslipidemia is a major focus in the management of Coronary 
Artery disease. Inspite of the wide array of drugs prescribed to patients, the response to 
drugs differ between individuals, so is the lipid profile. This has led to focus upon the 
genetic predisposition of people to atherosclerosis and the different patterns observed. 
These non modifiable risk factors have to be analyzed in population belonging to various 
ethnic origins and the treatment approach should be streamlined according to the 
population. The risk factors for atherosclerosis among developing countries also differ 
from those of developed countries. 
Peripheral vascular disease has been increasingly gaining importance as a major cause of 
debilitation and death. While there are voluminous records of studies done on coronary 
artery and cerebrovascular diseases, Indian studies on peripheral vascular disease appear 
to be relatively scarce, the dearth more apparent among the south Indian population.  
The sinister role of Low density lipoprotein and recently that of lipoprotein(a) , and the 
protective role of HDL have been well established in Coronary and cerebro vascular 
disease. The same can be true for Peripheral vascular disease, only that it remains to be 
ascertained by more number of studies in native Indian population. The pathogenic role 
of lipoprotein(a) has long been a mystery, more mechanisms of action being discovered 
as researchers probe into it. Still, Lp(a) has not been approved widely as a conventional 
parameter in the lipid profile analysis, and it is not amenable to routine treatment with 
lipid lowering drugs.  
An equally interesting factor is the Transforming Growth Factor beta (TGF-β), which 
plays an extremely vital role in many of the normal physiologic and also pathologic 
events of the system. Its association with peripheral vascular disease has not been proved 
decisively yet. Powerful molecule as it is, the presence or absence of it could be central to 
the evolution of the atherosclerotic plaque. Its level has been influenced by a wide variety 
of conditions and factors, one among them is lipoprotein(a).  
An insight into these intriguing factors has led to the performance of this study, whose 
Aims are: 
To study the levels of lipoprotein(a) and transforming growth factor-β in 
atherosclerotic peripheral vascular disease patients from the south Indian 
population, and to assess the predictive power of Lp(a) as a marker of peripheral 
vascular disease. 
To study the relationship between the levels of Lp(a) and TGF-β and establish the 
correlation. 
To determine the relation of other conventional risk factors of atherosclerosis with 
Lp(a) in peripheral vascular disease. 
To evaluate the possibility of setting a cut off value for Lp(a) and TGF-β, above 
which PVD risk can be assessed. 
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MATERIALS AND METHODS 
After obtaining approval from the Institutional Ethical Committee of Madras Medical 
College and Rajiv Gandhi Govt Gen Hospital, the study was conducted in the Department 
of Vascular surgery in RGGGH. 
STUDY POPULATION 
CASES 
The study sample comprised 50 unrelated south Indian Peripheral Vascular 
Disease patients (47 male , 3 female ) of Mean age 51.96 +/- 10.1 years. Inclusion criteria 
was ABPI (Ankle Brachial Pressure Index) less than 0.9 in the affected limb. All patients 
with systemic hypertension, acute infection and inflammatory disorders, liver or renal 
disease, thrombotic tendencies and metastatic conditions were excluded. Peripheral 
vascular disease other than that due to Atherosclerosis was also excluded (eg. 
Thromboangitis obliterans, autoimmune diseases) 
CONTROL SUBJECTS 
Controls were recruited from Master health Check-up. Apparently healthy 
individuals matched for age and sex were included. All of them were free from symptoms 
and signs of peripheral arterial disease. 
Sample collection and Processing 
  3 mL of blood was collected into a plain tube by Venipuncture after overnight 
fasting. The blood was allowed to clot and Serum was separated by centrifugation. 0.5 
mL of serum was stored in two eppendorf tubes at -20o C for analysis of Lipoprotein (a) 
and TGF β. The levels of total cholesterol, triglycerides and high density lipoprotein were 
measured in XL 300 fully automated analyzer by colorimetric methods using 
commercially available kits within 6 hrs of blood collection. 
LIPID PROFILE 
The biochemical parameters undertaken for the study were determined using the 
following methodologies: 
ESTIMATION OF TOTAL CHOLESTEROL 
Kit used 
 Erba Mannheim XL system pack 
Methodology  
 CHOD-PAP  
Principle  
                                     CE 
Cholesterol esters                             Cholesterol + Fatty acids 
                                    CO 
Cholesterol + O2                                Cholest- 4-en-3-one + H2O2  
                                           POD 
2 H2O2  + Phenol+ 4 AAP                     Quinoeimine Dye  + 4 H2O     
 
CE      = Cholesterol Esterase 
CO      = Cholesterol Oxidase 
 4AAP = 4-amino antipyrine 
POD    = Peroxidase 
The concentration of cholesterol in the sample is directly proportional to the intensity of 
the red complex (red quinone), which is measured at 505nm.    
REAGENT COMPOSITION 
Active Ingredients     Concentration 
Pipes buffer ( pH 7.0)     35 mmol/L 
Sodium Cholate     0.5 mmol/L 
Cholesterol Oxidase     >0.1 U/mL 
Cholesterol Esterase     >0.2 U/mL 
Peroxidase      >0.8 U/mL 
4-amino antipyrine     0.5 mmol/L 
Phenol       28 mmol/L 
Reagents supplied were ready to use  
Calibrator 
 Total Cholesterol – 200 mg/dL 
Assay paramaters 
Assay type   - 1-Point 
Wavelength primary  - 505 nm 
Wavelength secondary - 0 
Sample volume  - 3 µL 
Reagent volume  - 300 µL 
Reaction direction  - Increasing 
Calibration curve  - Straight 
Reference values 
Male      : 120 – 250 mg/dL 
Female  : 110 – 230 mg/dL 
ESTIMATION OF TRIGLYCERIDE 
Kit Used 
 Erba Mannheim system pack 
Methodology 
 GPO-ADPS 
 
Principle 
                                      LPL 
Triglycerides + H2O                                   Glycerol + Free fatty acids 
                                   GK 
Glycerol + ATP                                                Glycerol-3-phosphate + ADP 
                                            GPO 
Glycerol-3-phosphate + O2                       DAP + H2O2 
                                          POD 
H2O2  + 4 AAP + ADPS                       Quinoneimine dye + H2O 
 
LPL - Lipoprotein Lipase 
GK - Glycerol Kinase 
ATP - Adenosine Triphosphate 
ADP - Adenosine Diphosphate 
GPO - Glycerol Phosphate Oxidase 
DAP - Dihydroxy Acetone phosphate 
ADPS - 4 Chlorophenol 
 The intensity of red color produced is proportional to the concentration of triglycerides 
and is measured at 546 nm. 
REAGENT COMPOSITION 
Active Ingredients     Concentration 
R1 
Pipes buffer (pH 7.0)     40 mmol/L 
4-Amino antipyrine     0.4 mmol/L 
ATP       1.5 mmol/L 
Mg2+         1.6 mmol/L 
Glycerol Kinase     > 66.67 µkat/L 
Glycerol 3 phosphate oxidase    > 60.00 µkat/L 
R2 
ADPS       0.6 mmol/L 
Peroxidase      > 20.00 µkat/L 
Lipoprotein Lipase     > 16.67 µkat/L 
 
 
REAGENT PREPARATION 
Reagents supplied were ready for use 
CALIBRATOR 
 Serum Triglyceride – 200 mg/dL 
ASSAY PARAMETERS 
Assay Type   1 point 
Wavelength primary  546 nm 
Wavelength secondary 0 
Sample volume  3 µL 
R1 vol    240 µL 
R2 vol    60 µL 
Reaction direction  Increasing 
Calibration curve  Straight 
REFERENCE VALUES 
Male  : 40 – 160 mg/dL 
Female: 35 – 135 mg/dL 
 
ESTIMATION OF HDL CHOLESTEROL 
Kit used 
 Erba Mannheim system pack 
Methodology 
 Immunoinhibition 
Principle 
Chylomicrons, VLDL, and LDL fractions in plasma are separated from HDL by 
Immunoinhibition. LDL, VLDL, and chylomicron (CM) react with PVS (Polyvinyl 
sulfonic acid) and PEGME ( Polyethylene glycol methyl ester) and the reaction results in 
inaccessibility of LDL, VLDL and CM by cholesterol oxidase (CHOD) and cholesterol 
esterase (CHER). The enzymes selectively react with HDL to produce H2O2  which is 
detected through a Trinder reaction.  
REAGENT COMPOSITION 
R1 
MES buffer     6.5 mmol/L 
N,N Bis(4-sulfobutyl)-3-methylaniline 3 mmol/L 
Polyvinyl sulfonic acid   50 mg/L 
Polyethylene glycol methyl ester  30mL/L 
MgCl2       2 mmol/L 
EDTA 
Detergent 
R2 
MES buffer (pH 6.5)    50 mmol/L 
Cholesterol esterase    5 kU/L 
Cholesterol Oxidase    20 kU/L 
Peroxidase     kU/L 
4-amino antipyrine    0.9 g/L 
Detergent     0.5% 
 
 
REAGENT PREPARATION 
Reagents supplied were ready for use 
Calibrator 
 HDL Cholesterol – 60 mg/dL 
ASSAY PARAMETERS 
Assay type    2 point 
Wavelength primary   600 nm 
Wavelength secondary  700 nm 
Sample volume   3 µL 
R1 volume    210 µL 
R2 volume    70 µL 
Reaction Direction   Increasing 
Calibration Curve   Straight 
Reference Values 
Male       : 35.3 to 79.5 mg/dL 
Female   : 42 to 88 mg/dL 
ESTIMATION OF VLDL and LDL CHOLESTEROL 
These parameters were calculated using Friedwald’s formula given below: 
 LDL-C       = TC-(HDL-C+ VLDL-C) 
 VLDL-C     = TGL/5 
 
 
 
ESTIMATION OF LIPOPROTEIN (a) 
Kit Used 
 Lp(a) Turbilatex kit from Spinreact 
Methodology 
 Immunoturbidimetry 
Principle 
 
 Latex particles coated with antibodies anti-Lp(a) are agglutinated when mixed with 
samples containing Lp(a). The agglutination causes an absorbance change, dependent 
upon the Lp(a) contents of sample that can be quantified at 570 nm by comparison from a 
calibrator of known Lp(a) concentration. The assay was done in a spectrophotometer 
Helios  
Reagents  
Diluent (R1)   - Glycine buffer 50 mmol/L pH 9.0, Sodium azide 0.95 g/L 
Latex (R2)      - latex particles coated with mouse monoclonal anti Lp(a), pH 8.2, Sodium 
Azide 0.95 g/L 
Calibrator 
Was reconstituted with 1 mL of NaCl (normal saline). Concentration of Lp(a) 100.8 
mg/dL. The  following dilutions were prepared. 
Calibrator 
Dilution 
1 2 3 4 5 
Lp(a) 
calibrator 
µL 
NaCl 0.9 
g/L     µL 
0 
100 
25 
75 
50 
50 
75 
25 
100
0 
Factor 0 0.25 0.5 0.75 1.0 
 
Procedure 
Assay conditions:   
 Temperature – 37o C 
Wavelength   -  570 nm (540-600 nm) 
Cuvette light path – 1 cm 
R1 volume   -  800 µL 
R2 volume   - 200 µL 
Sample/ Calibrator volume – 15 µL 
The reagents and sample were mixed well and the absorbance was read immediately (A1) 
and after 4 minutes (A2). 
  CALCULATIONS  
Calibration curve : The absorbance differences (A2-A1) of each Lp(a) calibrator was 
calculated and the values obtained were plotted against the Lp(a) concentration in 
a calibration curve. Lp(a) concentration in the sample was calculated by 
interpolation of its (A2-A1) in the calibration curve. 
Reference values 
 Normal values upto 30 mg/dL 
 
ESTIMATION OF TGF β 
Kit Used 
 DRG TGF-β1 ELISA kit 
Methodology 
 Enzyme Immunoassay 
 
 
Principle 
This is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the 
sandwich principle. 
Prior to testing the standards and patient samples are diluted in assay buffer, acidified 
with HCl and then neutralized with NaOH. Afterwards, the neutralized standards and 
samples are added to the antibody coated (polyclonal) microtiter wells. After the first 
incubation the unbound sample material is removed by washing. Then a monoclonal 
mouse anti TGF-β1 antibody, a biotinilated anti mouse IgG antibody and the 
Streptavidin-HRP Enzyme complex are incubated in succession. An immunoenzyme 
sandwich complex is formed. 
After incubation the unbound conjugate is washed off. Having added the substrate 
solution, the intensity of colour developed is proportional to the concentration of TGF β1 
in the patient sample. 
Reagents 
1. Microtiterwells, 12x8 (break apart) strips, 96 wells; 
Wells coated with anti-TGF-β1 antibody (polyclonal). 
2. Standard (Stock Standard), 1 vial, 2 mL, 
Concentrations: 600 pg/mL 
3. Assay Buffer, 10X concentrate, 1 vial, 10 mL, 
Concentrations: 0 pg/mL 
4. Antiserum, 1 vial, 11 mL, ready to use, 
monoclonal Mouse anti-TGF-β1 
5. Enzyme Conjugate, 1 vial, 11 mL, ready to use, 
anti Mouse IgG conjugated to Biotin. 
6. Enzyme Complex, 1 vial, 11 mL, ready to use 
Streptavidin Peroxidase 
7. Substrate Solution, 1 vial, 14 mL, ready to use, 
Tetramethylbenzidine (TMB). 
8. Stop Solution, 1 vial, 14 mL, ready to use, 
contains 0.5M H2SO4, 
9. Wash Solution, 1 vial, 30 mL (40X concentrated), 
10. 1 N HCl, 1 vial, 3 mL, ready to use, for acidification of the samples. 
11. 1 N NaOH, 1 vial, 3 mL, ready to use, for neutralization. 
The stock standard was kept frozen at -20oC until analysis.  
Reagent preparation 
All the reagents were brought to room temperature prior to use 
Assay Buffer 
10 mL of concentrated assay buffer was diluted with 90 mL of deionized water to a final 
volume of 100 mL working assay buffer. 
Standards 
Serial dilution of stock standard (600 pg/mL) was prepared as follows: 
Description Concentration 
Standard A 600 pg/mL 
Standard B 1 mL Standard A + 1 mL Assay Buffer 300 pg/mL 
Standard C 1 mL Standard B + 1 mL Assay Buffer 150 pg/mL 
Standard D 1 mL Standard C + 1 mL Assay Buffer 75 pg/mL 
Standard E 1 mL Standard D + 1 mL Assay Buffer 38 pg/mL 
Standard F 1 mL Standard E + 1 mL Assay Buffer 19 pg/mL 
Standard G     2 mL Assay Buffer    0 pg/mL 
Wash solution 
30 mL of concentrated wash solution was diluted with 1170 mL of deionized water to a 
final volume of 1200 mL. 
Specimen dilution 
Serum and Plasma Samples were diluted 1:50 with Assay Buffer prior to testing as 
follows 
 10 μL Serum + 490 μL Assay Buffer (mixed thoroughly) 
Acidification and Neutralization of Samples and Standards 
1. 200 μL Standards or prediluted Sample added into Reaction Caps ( Eppendorf-Caps). 
2. 20 μL 1 N HCl added to all caps 
3.  mixed thoroughly (vortex) and let stand for 15 minutes 
4. 20 μL 1N NaOH added for neutralization and mixed thoroughly. 
5. After neutralization the sample had a pH value between 7 and 8.  
Test Procedure 
Instrument used- Triturus automated ELISA machine 
1. the Microtiter wells were set in the frame holder. 
2. 100 μL of each pretreated Standard, Control and samples dispensed with new 
disposable tips into appropriate wells. 
3. plates covered and incubated for 3 hours incubation at room temperature. 
4. the wells were Rinsed 3 times with diluted wash solution, 300 μl per Well. Washing 
performed with the washer. 
5. 100 μL Antiserum Dispensed into all wells. 
6. Incubated for 120 minutes at room temperature. 
7. the wells Rinsed 3 times with diluted wash solution, 300 μl per Well.  
8. 100 μl Enzyme Conjugate (Anti Mouse Biotin) Dispensed into each well. 
9. Incubated 45 minutes at room temperature. 
10. the wells Rinsed 3 times with diluted wash solution, 300 μl per Well.  
11. 100 μl Enzyme Complex Dispensed into each well. 
12. Incubated 45 minutes at room temperature. 
13 the wells Rinsed 3 times with diluted wash solution, 300 μl per Well.  
14. 100 μL of Substrate Solution Added  to each well. 
15. Incubated for 15 minutes at room temperature. 
16. the enzymatic reaction Stopped by adding 50 μL of Stop Solution to each well. 
17. the absorbance (OD) of each well Determined at 450 ± 10 nm with a microtiter plate 
reader, within 10 minutes of adding the stop solution. 
 Calculation of Results 
1. the average absorbance values for each set of standards, controls and patient samples 
were Calculated. 
2. Using semi-logarithmic graph paper, a standard curve was constructed by plotting the 
mean absorbance obtained from each standard against its concentration with absorbance 
value on the vertical (Y) axis and concentration on the horizontal (X) axis. 
3. Using the mean absorbance value for each sample the corresponding concentration was 
determined from the standard curve. 
 
 
 
 
 
 
 
STATISTICAL 
ANALYSIS 
 
 
 
 
 
STATISTICAL ANALYSIS 
 
The statistical software SPSS pc+ (Statistical Package for Social Science) was used for 
statistical analysis. 
Mean and Standard deviation were estimated from the sample each study group. The 
mean values were compared by students’ t-test to calculate the p value. P value < 0.005 
was considered significant. 
Chi square test was used for comparison of the variables between controls and cases. 
Scatter diagrams were plotted to show the relationship between cases and controls on the 
levels of Lp(a) and TGF-β 
Pearson’s Correlation analysis was used to correlate the levels of Lp(a) and TGF-β. 
Charts were plotted for the significant lipid parameters to highlight their levels in cases 
and controls. 
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RESULTS 
 
 
 
 
TABLE-I : MASTER CHART CASES 
 
S.No  AGE 
yrs 
SEX  SMK  ALC  DM  BMI 
kg/m2 
Tot 
CHOL 
mg/dL 
TGL 
mg/dL
HDL 
mg/dL 
LDL 
mg/dL 
Lp(a) 
mg/dL 
TGF‐β 
pg/mL 
1  35  F  NO  NO  NO  18.8  156  148  38  88.4  34.9  264 
2  40  M  NO  YES  NO  23.7  188  156  40  116.8  31.1  203 
3  41  M  YES  YES  NO  25.2  181  148  41.5  109.9  37.9  185 
4  36  M  NO  NO  NO  27.2  253  131  44  182.8  38.5  165 
5  38  M  YES  YES  NO  28.6  238  157  36.5  170.1  36.9  200 
6  51  M  YES  YES  YES  32.5  156  169  30  92.2  73.4  136 
7  47  M  YES  YES  NO  20.3  197  189  25.8  133.4  53.6  174 
8  58  M  YES  YES  NO  32.4  293  194  31.2  223  75.9  146 
9  40  M  YES  YES  NO  34.6  286  253  36  199.4  84.7  120 
10  60  M  NO  YES  NO  28.3  230  295  28.5  142.5  82.7  128 
11  37  M  YES  YES  NO  21.8  215  186  31.0  146.8  58.5  342 
12  40  M  YES  YES  NO  27.9  176  185  34.3  104.7  60.8  179 
13  41  M  YES  YES  NO  28.2  200  158  41  127.4  55.1  156 
14  41  M  YES  YES  NO  29.8  250  175  39  177.4  40.3  214 
15  72  M  YES  YES  NO  25.3  245  252  35.6  159  85.7  108 
16  45  M  YES  YES  YES  34.5  310  271  32.0  223.8  75.4  138 
17  57  M  YES  YES  YES  26.0  186  220  41  101  71.6  196 
18  62  M  YES  YES  NO  19.6  135  152  32.5  72.1  74.5  208 
19  52  M  YES  YES  YES  27.4  278  253  33  194.4  89.2  124 
20  50  F  NO  NO  YES  18.8  136  125  42  69  30  286 
21  43  M  YES  YES  NO  22.5  120  165  41  46  37.2  242 
22  55  M  YES  NO  NO  28.6  200  268  36  110.4  87.1  140 
23  54  M  YES  YES  NO  29.1  186  235  40.5  98.5  51.3  200 
24  41  M  YES  YES  NO  25.4  186  135  38  121  23.6  346 
25  50  M  YES  YES  NO  20.2  146  102  32.5  93.1  65  210 
 S.No  AGE 
yrs 
SEX  SMK  ALC  DM  BMI 
kg/m2 
Tot 
CHOL 
mg/dL
TGL 
mg/dL
HDL 
mg/dL 
LDL 
mg/dL 
Lp(a) 
mg/dL
TGF‐β 
pg/mL 
26  53  M  YES  YES  YES  29.7  230  196  37.6  153.2  53.5  184 
27  75  M  NO  NO  YES  23.0  200  245  40.5  110.5  70.3  170 
28  55  M  YES  YES  NO  25.9  187  168  44  109.4  41.2  179 
29  49  M  YES  YES  YES  25.1  217  184  41  139.2  47.4  168 
30  45  M  YES  YES  NO  25.0  154  163  37  84.4  53.6  251 
31  65  F  NO  NO  YES  18.8  142  124  45  72.2  33.5  278 
32  65  M  NO  YES  YES  25.3  184  156  42  110.8  71.6  144 
33  57  M  YES  YES  NO  28.7  210  185  38  135  85.7  106 
34  49  M  YES  YES  YES  21.2  234  110  47.5  164.5  33  434 
35  61  M  YES  YES  NO  27.8  156  182  39.2  80.4  72.3  156 
36  54  M  YES  YES  YES  27.2  200  225  41.2  113.8  59.6  203 
37  40  M  YES  YES  NO  26.4  182  231  43.4  92.4  29.3  255 
38  60  M  YES  YES  YES  29.6  258  197  36.7  181.9  78.8  165 
39  49  M  YES  YES  YES  29.3  236  262  38.6  145  88.5  122 
40  56  M  YES  YES  NO  23.5  142  188  40.6  63.8  83  137 
41  45  M  YES  YES  NO  26.0  150  148  32  88.4  86.9  132 
42  52  M  YES  YES  YES  21.5  132  168  30  68.4  87.7  110 
43  47  M  YES  YES  YES  25.4  190  178  37.5  116.9  86.2  108 
44  60  M  YES  YES  YES  18.4  176  245  38  89  87.4  142 
45  52  M  YES  YES  NO  27.5  260  215  41.3  175.7  73.5  175 
46  70  M  YES  YES  YES  25.8  196  268  40.4  102  85.4  136 
47  63  M  YES  YES  YES  26.3  148  256  35.6  61.2  71.6  158 
48  53  M  NO  NO  YES  23.0  126  143  39.7  57.7  72.5  156 
49  70  M  YES  YES  NO  25.7  146  198  37  69.4  86  128 
50  68  M  NO  YES  NO  21.9  154  146  28.8  96  70.1  134 
TABLE- II : MASTER CHART CONTROLS 
S.No  AGE 
yrs 
SEX SMK  ALC  BMI 
(kg/m2)
T.CHOL 
(mg/dL)
TGL 
(mg/dL)
HDL 
(mg/dL) 
LDL 
(mg/dL) 
Lp(a) 
(mg/dL)
TGF‐β 
(pg/mL)
1  45  M  NO  NO  23.7  150  102  42.3  87.3  8.9  376 
2  60  M  NO  NO  23.5  110  115  40  47  12.0  410 
3  60  M  NO  YES  22.0  190  152  41.5  118.1  11.7  516 
4  40  M  NO  YES  23.5  162  125  50  87  8.2  569 
5  50  F  NO  NO  20.4  128  95  47  62  8.5  440 
6  65  M  NO  NO  22.1  148  142  52.5  67.1  13.3  477 
7  36  F  NO  NO  24.2  125  106  47.6  56.2  9.9  380 
8  45  M  YES  YES  22.9  165  127  41.6  98  12.6  302 
9  55  M  YES  NO  25.1  146  132  50  69.6  11.6  325 
10  68  M  NO  NO  20.2  150  100  45.7  84.3  10.7  372 
11  75  M  NO  YES  23.0  156  127  42  88.6  17.5  565 
12  56  M  YES   YES  25.7  148  121  41.7  82.1  17.9  565 
13  72  M  NO  NO  32.1  162  120  42.3  95.7  18.9  446 
14  45  M  NO  YES  23.7  148  111  45  80.8  8.5  534 
15  49  M  NO  NO  23.5  151  96  43  88.8  10.7  457 
16  50  M  YES   YES  23.0  162  105  41.6  99.4  10.8  476 
17  66  F  NO  NO  21.0  145  97  46.8  78.8  9.2  451 
18  51  M  NO  NO  23.6  145  98  48  77.4  10.2  468 
19  62  M  NO  NO  22.1  165  128  40.7  98.7  10.8  375 
20  52  M  YES   YES  23.6  146  135  49.2  69.8  9.6  527 
21  49  M  NO  NO  22.7  175  108  45.4  108  12.2  434 
22  47  M  NO  NO  25.2  183  125  43.5  114.5  9.9  560 
23  52  M  NO  NO  22.2  163  117  44  95.6  10.9  493 
24  40  M  YES   NO  23.0  153  97  47  86.6  9.5  418 
25  40  M  YES  YES  25.1  188  119  44.3  119.9  10.2  439 
 
S.No  AGE 
yrs 
SEX SMK  ALC  BMI 
(kg/m2)
T.CHOL 
(mg/dL)
TGL 
(mg/dL)
HDL 
(mg/dL) 
LDL 
(mg/dL) 
Lp(a) 
(mg/dL)
TGF‐β 
(pg/mL)
26  49  M  NO  NO  25.0  175  102  43.6  111  9.5  514 
27  41  M  YES  NO  23.5  159  121  47.2  87.6  8.9  394 
28  53  M  NO  NO  25.4  149  119  45  80.2  10.5  491 
29  40  M  NO  NO  24.9  168  97  45.2  103.4  7.1  585 
30  47  M  NO  NO  23.3  154  123  42.7  86.7  10.2  529 
31  42  M  NO  NO  23.2  147  103  41.8  84.6  10.1  352 
32  57  M  NO  NO  22.9  173  121  38.6  110.2  12.15  420 
33  60  M  YES  YES  21.8  169  121  38  106.8  20.5  380 
34  62  M  NO  NO  23.7  157  118  40  93.4  18.1  294 
35  62  M  NO  NO  22.7  148  121  42.5  81.3  18.7  326 
36  37  M  YES  NO  25.1  193  101  47.6  125.2  9.6  572 
37  70  M  NO  NO  19.5  170  116  44.2  102.6  21.5  542 
38  53  M  YES  NO  19.7  148  92  43.5  86.9  11.7  511 
39  54  M  YES  YES  23.1  173  106  42  109.8  12.9  438 
40  51  M  NO  NO  26.1  192  126  47.3  119.3  12.6  394 
41  38  M  NO  NO  23.7  145  86  53.5  74.3  10.2  494 
42  41  M  YES  YES  22.8  125  143  47.2  49.2  13.0  486 
43  58  M  NO  NO  23.0  155  131  43.8  85  13.4  476 
44  70  M  NO  NO  20.8  173  48  41.7  111.7  15.6  346 
45  38  M  NO  YES  22.7  136  82  50.6  69  9.9  642 
46  43  M  NO  NO  23.0  160  105  44  95  12.0  573 
47  41  M  YES  YES  25.5  168  137  44.2  96.4  14.7  537 
48  54  M  NO  YES  24.5  183  127  42.0  115.6  13.8  570 
49  55  M  NO  NO  22.8  140  106  44  74.8  13.2  565 
50  52  M  NO  NO  23.0  152  108  46.7  83.7  12.6  583 
 
 
TABLE- III : CHARACTERISTICS OF PATIENTS WITH PAD AND OF CONTROLS     
 Group N Mean 
Std. 
Deviation 
p value 
Age in 
years 
  
Control 50 51.96 10.12 0.992 
Cases 
50 51.98 10.23
BMI 
  
Control 50 23.37 1.96 <0.001** 
Cases 50 25.69 3.97
Total 
Chol 
  
Control 
50 157.52 17.72
<0.001** 
Cases 50 195.14 47.25
TGL 
  
Control 50 113.20 17.96 <0.001** 
Cases 50 190.06 47.72
HDL 
  
Control 50 44.59 3.40 <0.001** 
Cases 50 37.47 4.75
LDL 
  
Control 50 90.10 18.38 <0.001** 
Cases 50 119.68 44.28
Lp(a) 
  
Control 50 12.13 3.32 <0.001** 
Cases 50 63.27 20.52
TGF 
  
Control 50 467.78 85.60 <0.001** 
Cases 50 182.82 67.30
** denotes significance at 1% level (highly significant) 
 
 TABLE IV : COMPARISON OF LEVELS OF Lp(a) AND TGF-β AMONG DIABETICS 
& NON DIABETICS 
 DM Mean Std. Deviation 
P value 
Lp(a) 
  
Yes 
68.33 19.32 
0.157 (NS) 
No 
59.89 20.92 
TGF 
  
Yes 
177.9 76.96 
0.667 (NS) 
No 
186.1 61.18 
NS – Not significant at 5% level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE Va : Correlation between Lp(a) and TGF-β  - CASES 
  
    Lp(a) TGF 
Lp(a) Pearson Correlation 1 -.750(**)
Sig. (2-tailed) 
. .000
N 
50 50
TGF Pearson Correlation -.750(**) 1
Sig. (2-tailed) 
.000 .
N 
50 50
**  Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
 
 
 
 
 
TABLE Vb : Correlation between Lp(a) and TGF-β  - CONTROLS 
 
     Lp(a) TGF 
Lp(a) Pearson Correlation 
1 -.150
Sig. (2-tailed) 
. .299
N 
50 50
TGF Pearson Correlation 
-.150 1
Sig. (2-tailed) 
.299 .
N 
50 50
 
 
 
 
 
 
 
 TABLE VIa : Correlation between other lipid parameters with Lp(a) 
and   TGF-β - CASES 
 
 
    Lp(a) TGF- β 
Total 
Cholesterol 
Pearson Correlation .131 -.143
Sig. (2-tailed) .363 .323
N 50 50
TGL Pearson Correlation .552(**) -.478(**)
Sig. (2-tailed) .000 .000
N 50 50
HDL Pearson Correlation -.468(**) .363(**)
Sig. (2-tailed) .001 .010
N 50 50
LDL Pearson Correlation .071 -.088
Sig. (2-tailed) .626 .544
N 50 50
**  Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
 
TABLE VIb : Correlation between other lipid parameters with Lp(a) and   
TGF-β - CONTROLS 
 
  
    Lp(a) TGF- β 
Total Cholesterol Pearson Correlation .116 .092
Sig. (2-tailed) .423 .524
N 50 50
TGL Pearson Correlation .213 .032
Sig. (2-tailed) .137 .827
N 50 50
HDL Pearson Correlation -.433(**) .262
Sig. (2-tailed) .002 .066
N 50 50
LDL Pearson Correlation .138 .051
Sig. (2-tailed) .338 .727
N 50 50
**  Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
 
 
 
 
FIGURE 1  :  MEAN BMI & LIPID PROFILE IN CASES AND CONTROLS 
 
 
 
 
 
 
 
 
 
 
  
FIGURE 2  :  MEAN Lp(a) AND TGF- β IN CASES AND CASES 
 
 
 
 
 
 
 
 
 
 
 
[[[[[ 
 
FIGURE 3 : Lp(a) LEVELS AMONG CASES AND CONTROLS 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4 : TGF- β LEVELS AMONG CASES AND CONTROLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE  5 : MEAN BMI FOR CASES AND CONTROLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE  6  : MEAN TOTAL CHOLESTEROL FOR CASES AND          
CONTROLS 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7 : MEAN TGL FOR CASES AND CONTROLS 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE  8 : MEAN LDL FOR CASES AND CONTROLS 
 
 
 
 
 
 
 
 
 
 
 
FIGURE  9 : MEAN HDL FOR CASES AND CONTROLS 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 10 : MEAN Lp(a) FOR CASES AND CONTROLS 
 
 
 
 
 
 
 
 
 
 
 FIGURE 11 : MEAN TGF-β FOR CASES AND CONTROLS 
 
 
 
 
 
 
 
 
RESULTS 
  The age, sex, Body Mass Index, serum lipid levels, Lp(a) and TGF-β levels of the 50 patients of 
Atherosclerotic peripheral Vascular disease are listed in Table I.  
The age, sex, Body Mass Index, serum lipid levels, Lp(a) and TGF-β levels of the 50 healthy 
controls are listed in Table II. 
The mean values of the studied parameters of the patients were compared with that of the 
controls using students’ independent t-test in Table III. P value <0.05 was taken as significant. 
Mean BMI for cases with PVD (25.6 +/- 3.9) is significantly higher than the mean BMI for 
controls (23.3 +/- 1.9). (p < 0.01) 
Mean serum total cholesterol level in cases (157.5 +/- 17.7) is significantly higher than that of 
the controls (195.1 +/- 47.2) (p < 0.01) 
Mean serum Triglycerides in cases (190.1 +/- 47.7) is significantly higher than that of controls 
(113.2 +/- 17.9) (p < 0.01) 
Mean serum LDL in cases (119.7 +/- 44.2) is significantly higher than that of controls (90.1 +/- 
18.3) (p < 0.01) 
Mean serum HDL in cases ( 37.4 +/- 4.7) is significantly lower than that of controls (44.5 +/- 
3.4) (p < 0.01) 
Mean serum Lp(a) in cases (63.2 +/- 20.5) is significantly higher than that of controls (12.1 +/- 
3.3) (p < 0.01). Mean serum TGF-β in cases (182.8 +/- 67.3) is significantly lower than that of 
controls (467.7 +/- 85.6) (p < 0.01) 
Thus increased BMI, total cholesterol, Triglyceride, Low Density Lipoprotein, decreased High 
density lipoprotein, increased Lipoprotein (a) and decreased TGF- β are significant contributing 
factors for the occurrence of Atherosclerotic peripheral vascular disease. 
Since Diabetes mellitus is a single most important factor that can contribute to both 
atherosclerotic PVD and increase in Lp(a), the means of the level of Lp(a) in patients with and 
without DM were compared in Table IV. There was no significant difference in the level of 
elevation of Lp(a) in these two groups so it can be inferred that Lp(a) contributes independently 
to the occurrence of PVD. 
Tables Va and Vb show The relationship between the levels of Lp(a) and TGF-β using the 
correlation analysis, in cases and controls, respectively. There was no statistically significant 
correlation between Lp(a) and TGF-β in control subjects but we found a strongly negative 
correlation between these two parameters in cases of PVD. 
Table VIa and VIb show the correlation between the levels of the lipid parameters Total 
Cholesterol, Triglyceride, HDL and LDL with Lp(a) and TGF-  β  among cases and controls, 
respectively. There is a statistically significant positive correlation with TGL levels and Lp(a), 
negative correlation with HDL and Lp(a), positive correlation with HDL and TGF- β, negative 
correlation with TGL and TGF-  β,  and this is among cases. The only significant correlation 
found among controls is between HDL and Lp(a), a negative one.Figures 1 through 11 show the 
mean levels of various parameters viz. BMI, Total Cholesterol, Triglyceride, HDL, LDL, 
Lipoprotein (a) and TGF- β in cases and controls. Figures 3 and 4 depict the distribution of the 
levels of Lp(a) and TGF- β among cases and controls by means of scatter diagram. 
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DISCUSSION 
Peripheral Vascular disease is an important health care problem in the developed countries117 and 
the concern is constantly increasing in the developing nations. Extensive research has been 
conducted on the prevalence, risk factors and patient characteristics in western countries, but 
very few studies have been done in India. The general prevalence of atherosclerotic PVD is 
found to be higher in western countries than South Asian population. There are differences in the 
risk factors based on ethnicity, as shown in many of the studies. 
The incidence of atherosclerotic PVD is on the rise rampantly and exponentially in India due to 
the following reasons: sheer increase in population size due to natural growth, ageing of the 
population which makes them more vulnerable to chronic diseases (advanced age is an important 
risk factor for atherosclerosis and PVD), increased vulnerability due to life style changes that 
promote PVD, India becoming the Diabetic capital of the world (the occurrence of 
atherosclerotic complications is several times more pronounced and severe in diabetics). 
S.A.V.E (Stroke, Aneurysm and Vascular Evaluation) India project is a study aimed  to 
determine the incidence and prevalence of Stroke, Aneurysms and Occlusive Peripheral Vascular 
Disease (PVD) in the Indian population, to determine atherosclerotic and non-atherosclerotic risk 
factors , to assess appropriateness of utilization of diagnostic imaging in the screening and to 
diagnose the same in a timely fashion for early treatment of life and limb threatening vascular 
conditions. 
This study has attempted to determine the characteristics of atherosclerotic PVD and the risk 
factors in a south Indian population, the subjects mainly belonging to tamilnadu, some of them 
having origin in Andhra Pradesh. But there did not seem to be any gross difference in the 
measured parameters between them, so they are evaluated as a single group of cases.   
The gender distribution of cases in this present study is 47 males and 3 females, 2 of the females 
in the post menopausal age group. This clearly shows that male sex is in itself a risk factor for 
atherosclerotic PVD, estrogen being protective in women till menopause.  
The conventional risk factors like increased BMI, total cholesterol, triglycerides and LDL and 
decreased HDL are significantly higher in the cases, emphasizing their causative role once again. 
Hypertriglyceridemia seems to be more common than hypercholesterolemia, the TGL levels on 
the upper level even in the controls. Also, HDL cholesterol level was on the lower limit in cases 
and just adequately normal in most of the controls.  
This study has given importance to evaluate the association of lipoprotein(a) in atherosclerotic 
PVD and its relation to an essential antiatherogenic factor, TGF-β. While the role of TGF- β in 
atherosclerosis has been studied extensively, there have been few studies relating to 
atherosclerotic PVD. The relationship between Lp(a) and TGF- β has been described since years 
ago, that Lp(a) affects the activity of TGF  β adversely. This study is the first to evaluate this 
relationship in atherosclerotic PVD in a south Indian population. Since TGF β has shown to be 
associated independently with hypertension, and the pathogenesis of hypertension is both 
interlinked and many a times confounding with atherosclerosis, it was decided to exclude 
systemic hypertension from the study. 
The levels of Lp(a) are increased to enormous proportions in cases than controls, and the TGF 
levels are decreased in the same. The distribution of TGF levels is wide as seen in the scatter 
diagram, both in cases and controls. There is negative correlation between Lp(a) and TGF β only 
in cases and not in controls. 
This is because of the extensive cytokine interactions in atherosclerosis and in normal 
individuals as such. Lp(a) is not the only factor that affects TGF beta, but it definitely affects its 
adversely when present in excess. The level of Lp(a) is in turn determined by the genetic 
arrangement of apo(a) gene. The level of Lp(a) is inversely proportional to the number of kringle 
repeats in the apo(a) gene.  
Lp(a) shows positive correlation with TGL and not total cholesterol or LDL in cases, and there is 
no significant correlation in controls, possibly due to the genetic makeup of the cases. Negative 
correlation is seen with HDL both in cases and controls, proving that HDL is protective. TGF 
beta has no association with any of the lipid parameters in controls but has negative correlation 
with TGL and significant positive correlation with HDL in cases.  
This study has shown that Lp(a) is a  causative factor for atherosclerotic PVD. The fact is not 
forgotten that the rise in its levels is also an effect of other etiological parameters like smoking, 
alcoholism and especially, Diabetes Mellitus. Its levels were analyzed between diabetics and non 
diabetics, a slight increase in mean levels was noted in diabetics, but still statistically not 
significant. So Lp(a) can be considered an independent risk factor for atherosclerotic peripheral 
vascular disease. 
 In addition to its well established mechanisms of pathogenesis, atherogenicity due to the 
constituent LDL particle and thrombogenicity due to the apo(a) moiety which has structural 
analogy with plasminogen and so inhibits fibrinolysis, the theory that Lp(a) stimulates smooth 
muscle proliferation by inhibiting the protective TGF beta, has been well substantiated in this 
study.  
 
 
 
This could open up a wide arena for research in order to answer the following unanswered 
questions in this study: 
 Why is there wide variation in the levels of TGF beta among apparently healthy 
individuals?  
 Why isn’t there a consistent proportion of decrease of TGF beta with increase in Lp(a)? 
 Does the genetic arrangement of Lp(a) affect the gene expression of TGF beta? If so 
how? 
 What are the other factors that play intermediary role between the various lipid 
parameters and TGF beta? 
The knowledge of the answers to these unanswered questions can help in making atherosclerotic 
PVD more amenable to treatment and provide better quality of life for the affected.  
 
 
 
 
 
 
 
  
 
 
 
 
 
CONCLUSION 
 
 
 
 
CONCLUSION 
From the results of the study it can be concluded that, 
Increased level of Lipoprotein (a) and decreased level of TGF-β are independent risk factors for 
atherosclerotic peripheral vascular disease, along with the other established risk factors – 
Smoking, Alcoholism, Diabetes mellitus, Increased body mass index, Increased total 
Cholesterol, Increased Triglyceride, Increased Low Density Lipoprotein and Decreased High 
Density lipoprotein. 
Lipoprotein (a) inhibits TGF-β and decreases its level in the blood, the inhibition more 
pronounced at higher levels of Lp(a). 
Hypertriglyceridemia is a more significant risk factor than hypercholesterolemia. 
High Density Lipoprotein is protective against atherosclerotic peripheral vascular disease. 
Estimation of Lipoprotein (a) can be included in the routine analysis of lipid profile in patients 
with atherosclerotic peripheral vascular disease. 
 
 
 
 
 
 
 
 
 
FUTURE PROSPECTS 
OF THE STUDY 
 
 
 
 
 
 
 
FUTURE PROSPECTS OF THE STUDY 
 
a. Studies on a larger scale can be undertaken in different parts of India and Asia to 
establish definite cut off values for Lp(a) and TGF-β according to the ethnicity and 
lifestyle. 
b. Genetic studies focusing on the gene pattern of lipoprotein (a), the apo A gene, and its 
influence over the levels of serum Lp(a) and relationship with TGF-β, can be encouraged 
since it will give a clearer insight into the pathogenic relationship between them. 
c. Research aimed at developing drugs against Lipoprotein (a)  and its pathologic 
consequences can be done. 
d. Further research works focused on identifying strategies to improve the TGF-β activity in 
the needful, can be performed. 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
1 Cronenwett, R. Rutherford's Vascular Surgery. 7 edn. 
2 Merck Manual of Diagnosis and Therapy Professional Edition. 
3 John P. Cooke, M., PHD,* Andrew M. Wilson, MBBS, PHD. Biomarkers of Peripheral 
Arterial Disease. Journal of the American College of Cardiology Vol. 55 (2010). 
4 P.C. BENNETT1, S. SILVERMAN2, P.S. GILL3 and G.Y.H. LIP1. Ethnicity and 
peripheral artery disease. Q J Med  102:3–16 (2009). 
5 Norgren L, H. W., Dormandy JA  33 Inter-Society Consensus for the Management of 
Peripheral Arterial Disease (TASC II). European journal of vascular and endovascular 
surgery : the official journal of the European Society for Vascular Surgery (Suppl 1): 
S1–75. ( 2007). 
6 Brunicardi, F. C.     (2004). 
7 Russell Ross, P. D. Atherosclerosis: An Inflammatory disease. NEJM vol. 3430, 115-124 
(1999). 
8 Davis M.J, M. J. M. Systemic Pathology. Vol. vol. 10 (Churchill Livingstone, 1995). 
9 Kumar V, A. A., Fausto N, et al   Robbins Basic Pathology. 8th ed edn,  (Elsevier 
Saunders, 2007). 
10 Torzewski J, B. D., Waltenberger J, et al       Processes in atherosclerosis: complement 
activation. Atherosclerosis (1997). 
11 Berliner JA, T. M., Sevanian A, et al     Minimally modified low density lipoprotein 
stimulates monocyte endothelial interactions. J Clin Invest 85:1260 (1990). 
12 Lindemann S, K. B., Daub K, et al    Molecular pathways used by platelets to initiate and 
accelerate atherogenesis. Curr Opin Lipidol  18:566 (2007). 
13 al, J. A. G. M. D. e. Multiple complex xoronary plaques in patients with AMI. NEJM vol. 
343, 915-922 (2000). 
14 Golledge J, G. R., Davies AH   The symptomatic carotid plaque. Stroke  31:774 (2000). 
15 GK, H. Inflammation, atherosclerosis, and coronary artery disease. The New England 
journal of medicine 352:1685 (2005). 
16 Liapis CD, B. K., Fernandes e Fernandes J, et al    Vascular Surgery.  (Springer-Verlag, 
2007). 
17 Kullo IJ, B. C. Conditional risk factors for atherosclerosis. Mayo Clin Proc 80:219 
(2005). 
18 Vidula H, T. L., Liu K, et al    Biomarkers of inflammation and thrombosis as predictors 
of near term mortality in patients with peripheral arterial disease: a cohort study. Ann 
Intern Med 148:85 (2008). 
19 Bartholomew JR, O. J. Pathophysiology of peripheral arterial disease and risk factors for 
its development. Clev Clin J Med 73:8 ( 2006). 
20 Pearson TA, M. G., Alexander RW, et al    Markers of inflammation and cardiovascular 
disease. Application to clinical and public health practice. A statement for healthcare 
professionals from the Centers for Disease Control and Prevention and the American 
Heart Association. Circulation 107:499 (2003). 
21 N.A. Boon, F. e. a. Davidson's principles and practice of medicine. 18th edition edn. 
22 Sullivan, J. L. Iron and the sex difference in Heart disease risk. Lancet vol 1, 1293-1294 
(1981). 
23 Walsh B.W Schiff I, R. B. e. a. Effects of postmenopausal estrogen replacement on the 
concentration and metabolism of plasma lipoproteins. NEJM 325, 1196-1204 (1991). 
24 David J Maron, P. M. R. e. a. Hurst - The Heart, Arteries and Veins.  (Mc Graw Hill). 
25 WC, K. The peripheral vascular consequences of smoking. Ann Vasc Surg 5:291-304 
(1991). 
26 S, H. Smoking as a risk factor for endothelial dysfunction. Can J Cardiol  14 (1998). 
27 Miller GJ, B. K., Cooper JA, et al     Activation of the coagulant pathway in cigarette 
smokers. Thromb Haemost 79:549-553 (1998). 
28 Rahman MM, L. I. Structural and functional alteration of blood vessels caused by 
cigarette smoking: an overview of molecular mechanisms. Current vascular 
pharmacology 5:276-292 (2007). 
29 Zevin S, S. S., Gourlay SG, et al   Cardiovascular effects of carbon monoxide and 
cigarette smoking. Journal of the American College of Cardiology 38:1633-1638 (2001). 
30 Bottcher M, F. E. Pathology of coronary arteries in smokers and non smokers. J 
Cardiovasc Risk 6; 299-302 (1999). 
31 Price JF, M. P., Lee AJ, et al     Relationship between smoking and cardiovascular risk 
factors in the development of peripheral arterial disease and coronary artery disease: 
Edinburgh Artery Study. Eur Heart J 20:344-353 (1999). 
32 Cole CW, H. G., Farzad E, et al    Cigarette smoking and peripheral arterial occlusive 
disease. Surgery 114:753-756 ( 1993). 
33 Rimm EB, W. P., Foscher K, et al. Meta-analysis of effects of alcohol on lipids and 
hemostatic factors. BMJ 319;1523-1528 (1999). 
34 Eckel RH, W. M., Chait A, et al    Prevention Conference VI: Diabetes and 
Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. 
Circulation 105:e138-e143 (2002). 
35 Beckman JA, C. M., Libby P     Diabetes and atherosclerosis: epidemiology, 
pathophysiology, and management. JAMA 287:2570-2581 (2002). 
36 Kaiser N, S. S., Feener EP, et al  Differential regulation of glucose transport and 
transporters by glucose in vascular endothelial and muscle cells. Diabetes 42:80-89 ( 
1993). 
37 Muniyappa R, Q. M. Insulin action and insulin resistance in vascular endothelium. Curr 
Opin Clin Nutr Metab Care 10:523-530 (2007). 
38 Koon Hov Mak, e. a. Emerging concepts in the management of AMI in patients with 
Diabetes Mellitus. Journal American College of Cardiology 3;268-298 (2000). 
39 al., S. H. H. e. The haplotype analysis suing multiple markers of the apolipoprotein B 
gene in patients with coronary artery disease. J Korean Med Sci 27;503-519 (2001). 
40 Gotto AM Jr. Powall, H. R. Introduction to the plasma lipoprotein. Methods Enzymology 
128 (1986). 
41 PN., D. Lipoprotein(a). Baillere's Clin End Metab 9;773-795 (1995). 
42 Wasan KM, B. D., Lee SD, Sachs-Barrable K, Thornton SJ  Impact of lipoproteins on the 
biological activity and disposition of hydrophobic drugs: implications for drug discovery. 
Nature Reviews Drug Discovery 7 (1): 84–99 (2008). 
43 Franceschini G, S. M., Gianfranceschi G, Sirtori CR   Relation between the HDL 
apoproteins and AI isoproteins in subjects with the AIMilano abnormality. Metab. Clin. 
Exp 30 (5): 502–9 (1981). 
44 Ma J, L. X., Lou B, Wu MP   Role of apolipoprotein A-I in protecting against endotoxin 
toxicity. Acta Biochim. Biophys. Sin. (Shanghai) 36 (6): 419–24 (2004). 
45 al, J. J. G. J. e. DNA polymorphism of the apolipoprotein B gene wihtr premature 
coronary artery disease. Atherosclerosis 82;17-17 (1990). 
46 al, F. M. e. A functional polymorphism of the apolipoprotein B promoter that influences 
the level of plasma low density lipoprotein. Journal of lipid research 40;1686-94 (1999). 
47 al, T. J. K. e. Complete protein sequence and identification of structural domains of 
human apolipoprotein B. Nature Reviews Drug Discovery 323 (1986). 
48 Utermann G, M. H., Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein 
phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma.  J. 
Clin. Invest 80 (2): 458–65 (1987). 
49 Guevara J Jr, K. R., Honda S, Northup SR, Morrisett JD. A structural assessment of the 
apo[a] protein of human lipoprotein[a]. Proteins 12 (1992). 
50 Howard BV, H. W. Joslin's Textbook of Diabetes. 13th ed edn,  (Lea & Febiger, 1994). 
51 HB, B. Increasing HDL cholesterol levels. The New England journal of medicine 
350:1491-1494 ( 2004). 
52 HIll SA, M. Reverse cholesterol transport a review of the process and its clin. 
Implications. Cl. Biochem 30;517-525 (1997). 
53 Phillipas MC, G. K., Haynes MP, Johnson WJ, Lund-Katsz S, Rothblat GH. Mechanism 
of High density lipoprotein- mediated efflux of cholesterol from the cell plasma 
membranes. Atherosclerosis 137 (1998). 
54 Jr, K. P. The antiatherogenic role of high density lipoprotein cholesterol. Am J 
Cardiology 82 (1999). 
55 al, W. J. e. Increased frequency of apolipoprotein B signal peptide sp 24/24 in patients 
with coronary artery disease. Clinical genetics 45;250-254 (1994). 
56 al, J. H. W. e. Apolipoprotein B 3' hyoervariable repeat genotype. Clin Chem 42;927-932 
(1996). 
57 Angles-Cano, E. Structural basis for the pathophysiology of lipoprotein(a) in the athero-
thrombotic process. Brazilian journal of medical and biological research = Revista 
brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et 
al.] 30, 1271-1280 (1997). 
58 Beisegel U, N. A., Wolf K, Reblin T & Rath M    Lipoprotein(a) in the arterial wall. 
European Heart Journal 11 (1993). 
59 Patthy L, T. M., Vàli Z, Bànyai L & Vàradi A  Kringles: modules specialized for protein 
binding. FEBS Letters 171: 131-136. (1984). 
60 A, T. The structure of domains of blood proteins. Thrombosis and Haemostasis 66: 16-31 
(1991). 
61 McLean J, T. J., Kuang W, Eaton D, Chen E, Fless G, Scanu AM & Lawn R. cDNA 
sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330 (1987). 
62 Guevara J, K. R., Honda S, Northup SR & Morrisett JD  A structural assessment of the 
apo(a) protein of human lipoprotein(a). Proteins 12: 188-199 (1992). 
63 Eaton D, F. G., Kohr W, McLean J, Xu Q, Miller C, Lawn R & Scanu AM. Partial amino 
acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. 
Proceedings of the National Academy of Sciences, USA 84 (1987). 
64 Anglés-Cano E, R. D. L. H. Plasminogen binding by a2-antiplasmin and histidine-rich 
glycoprotein does not inhibit plasminogen activation at the surface of fibrin. Biochimica 
et Biophysica Acta 1156: 34-42 (1992). 
65 Rouy D, G. P., Nigon F, Chapman J & Anglés-Cano E  Lipoprotein (a) impairs 
generation of plasmin by fibrinbound tissue-type plasminogen activator. Arteriosclerosis 
and Thrombosis 11: 629 (1991). 
66 Sato Y, T. R., Moses H & Rifkin DB. Characterization of the activation of latent TGF-b 
by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating 
system. Journal of Cell Biology 111: 757-763 (1990). 
67 Kojima S, H. P. R. D. Lipoprotein(a) inhibits the generation of transforming growth 
factor b: an endogenous inhibitor of smooth muscle cell migration. Journal of Cell 
Biology 113 (1991). 
68 Grainger DJ, K. P., Liu AC, Lawn RM & Metcalfe JC. Activation of transforming growth 
factor b is inhibited in transgenic apolipoprotein(a) mice. Nature 370 (1994). 
69 Levin EG, M. L., Fless GM, Scanu AM, Baynham PJ, Curtiss LK & Plow EF. 
Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial 
cells. Arteriosclerosis and Thrombosis 14: 438-442 (1994). 
70 van der Hoek YY, S. W., Côté GP, Kastelein JJP & Koschinsky ML  Binding of 
recombinant apolipoprotein(a) to extracellular matrix proteins. Arteriosclerosis and 
Thrombosis 14: 1792-1798 (1994). 
71 Naruszewicz M, S. E. D. J. Oxidative modification of lipoprotein(a) and the effect of b-
carotene. Metabolism 41: 1215-1224 (1992). 
72 Boerwinkle E, L. C., Lin J, Lackner C, Chiesa G & Hobbs HH Apolipoprotein(a) gene 
accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. 
Journal of Clinical Investigation 90 (1992). 
73 Lu H, C. L., Daugherty A   Atherosclerosis and arterial blood pressure in mice. Current 
drug targets 8:1181-1189 (2007). 
74 Franklin SS, K. S., Wong ND, et al. Is pulse pressure useful in predicting risk for 
coronary heart disease? The Framingham Heart Study. Circulation 100;354-360 (1999). 
75 Daugherty A, M. M., Cassis LA     Angiotensin II promotes atherosclerotic lesions and 
aneurysms in apolipoprotein E–deficient mice. The Journal of clinical investigation 
105:1605-1612 (2000). 
76 Landmesser U, D. H. Endothelial function and hypertension. Curr Opin Cardiol 22:316-
320 (2007). 
77 Yang XP, L. Y., Shesely EG, et al  Endothelial nitric oxide gene knock-out mice: cardiac 
phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial 
ischemia/reperfusion injury. Hypertension 34:24-30 (1999). 
78 Fava C, M. P., Patrignani P, et al:      . Renal artery stenosis and accelerated 
atherosclerosis:which comes first? Journal of hypertension 24:1687-1696 (2006). 
79 Chade AR, K. J., Rodriguez-Porcel M, et al   Comparison of acute and chronic 
antioxidant interventions in experimental renovascular disease. American journal of 
physiology. Renal physiology 286:F1079-F1086 (2004). 
80 M.D, G. N. W. Homocysteine and Atherothrombosis. NEJM 338;1042-1048 (1998). 
81 Lentz SR, S. J. Inhibition of thrombomodulin surface expression and protein C activation 
by the thrombogenic agent Homocysteine. The Journal of clinical investigation 88;190-
1914 (1991). 
82 Fryer RH, W. B., Gubler DB, et al. Homocysteine, a risk factor for premature vascular 
disease and thrombosis, induces tissue factor activity in endothelial cells. 
Arteriosclerosis, thrombosis, and vascular biology 13;1327-1333 (1993). 
83 Fuster V, G. A., Libby P, et al. Task Force1: Pathogenesis of coronary artery disease- 
The biologic role of risk factors. Journal of the American College of Cardiology 27;964-
976 (1996). 
84 Maresa G, B. A., Marcholi R Minno GD. Measuring plasma fibrinogen to rpedict stroke 
and myocardial infarction: An update. Arteriosclerosis, thrombosis, and vascular biology 
19;1368-1377 (1999). 
85 Tedgui, A. & Mallat, Z. Cytokines in atherosclerosis: pathogenic and regulatory 
pathways. Physiological reviews 86, 515-581, doi:10.1152/physrev.00024.2005 (2006). 
86 F, B. F. a. B. The cytokine network. Immunol Today 10: 299–304 (1989). 
87 Boulay JL, O. S. J., and Paul WE Molecular phylogeny within 
type I cytokines and their cognate receptors. . Immunity 19;159-163 (2003). 
88 Langer JA, C. E., and Kotenko S. The class II cytokine receptor (CRF2) family: overview 
and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev 15: 33–48 ( 
2004). 
89 CA, E. H. a. P. Modulation of epithelial and endothelial paracellular permeability by 
leukocytes. Adv Drug Deliv Rev 41: 315–328 ( 2000). 
90 Jr, C. M. a. G. M. Endothelial expression of a mononuclear leukocyte adhesion molecule 
during atherogenesis. Science 251: 788–791 (1991). 
91 Hsu HY, N. A., and Hajjar DP. Inhibition of macrophage scavenger receptor activity by 
tumor necrosis factor-alpha is transcriptionally and post-transcriptionally regulated. The 
Journal of biological chemistry 271:7767–7773 (1996). 
92 Minami M, K. N., Shimaoka T, Kataoka H, Hayashida K, kiyama Y, Nagata I, Ando K, 
Nobuyoshi M, Hanyuu M, Komeda M, Yonehara S, and Kita T. Expression of SR-PSOX, 
a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in 
human atherosclerotic lesions. Arteriosclerosis, thrombosis, and vascular biology 21: 
1796–1800 (2001). 
93 Sendobry SM, C. J., Welch K, Grusby MJ, and Daugherty A Absence of T lymphocyte-
derived cytokines fails to diminish macrophage 12/15-lipoxygenase expression in vivo. 
Journal of immunology 161: 1477–1482 (1998). 
94 Tellides G, T. D., Kirkiles-Smith NC, Kim RW, Wilson JH, Schechner JS, Lorber MI, 
and Pober JS Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. 
Nature 403:207–211 ( 2000). 
95 Maldonado-Lopez R, D. S. T., Michel P, Godfroid J, Pajak B, Heirman C, Thielemans K, 
Leo O, Urbain J, and Moser M. CD8alpha                                                 and CD8alpha 
subclasses of dendritic cells direct the development of distinct T helper cells in vivo  
The Journal of experimental medicine 189 (1999). 
96 AY., F. J. a. R. A well adapted regulatory contrivance: regulatory T cell development and 
the forkhead family transcription factor Foxp3. Nat Immunol 6: 331–337 (2005). 
97 Folcik VA, A. R., and Cathcart MK. . Cytokine modulation of LDL oxidation by 
activated human monocytes. . Arteriosclerosis, thrombosis, and vascular biology 17: 
1954–1961 (1997). 
98 Maziere C, A. M., and Maziere JC. Tumor necrosis factor enhances low density 
lipoprotein oxidative modification by monocytes and endothelial cells. FEBS Lett 338: 
43–46 (1994). 
99 AC, N. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and 
atherosclerotic plaque rupture. Physiological reviews 85: 1–31 (2005). 
100 Amento EP, E. N., Palmer H, and Libby P. . Cytokines and growth factors positively and 
negatively regulate interstitial collagen gene expression in human vascular smooth 
muscle cells. Arterioscler Thromb 11: 1223–1230 (1991). 
101 I, L. T. a. P. Current understanding of stem cell mobilization: the roles of chemokines, 
proteolytic enzymes, adhesion molecules, cytokines, and stromal cells Exp Hematol 30: 
973–981 (2002). 
102 Luttun A, T. M., Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, 
Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, 
Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, and Carmeliet P 
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor 
angiogenesis, arthritis and atherosclerosis. Nature medicine 8: 831–840 (2002). 
103 Virmani R, K. F., Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, and Narula J. 
Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source 
of intraplaque hemorrhage. Arteriosclerosis, thrombosis, and vascular biology 25: 2054–
2061 (2005). 
104 P, G. Y. a. L. Progression of atheroma: a struggle between death and procreation. 
Arteriosclerosis, thrombosis, and vascular biology 22:1370–1380 (2002). 
105 DC, M. M. a. A. Endothelial cell activation by leukocyte microparticles. Journal of 
immunology 161: 4382–4387 (1998). 
106 Marsman DS, C. R., Conway JG, and Popp JA. Relationship of hepatic peroxisome 
proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the 
peroxisome proliferators di(2-ethyl-hexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-
pyrimidinylthio] acetic acid (Wy 14,643) in rats. Cancer Res 48 (1988). 
107 properties, S. E. a. S. J. R. o. e. c. c. Modulation of tissue factor, plasminogen activator 
inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis 
factor. . The Journal of biological chemistry 264: 20705–20713 (1989). 
108 Wang C, D. L., Hong M, Akkaraju GR, Inoue J, and Chen ZJ  TAK1 is a ubiquitin-
dependent kinase of MKK and IKK. Nature 412:346–351 (2001). 
109 Grainger, D. J. Transforming growth factor beta and atherosclerosis: so far, so good for 
the protective cytokine hypothesis. Arteriosclerosis, thrombosis, and vascular biology 24, 
399-404, doi:10.1161/01.ATV.0000114567.76772.33 (2004). 
110 Kulkarni AB, W. J., Yaswen L, Mackall CL, Bauer SR, Huh CG, Gress RE, and Karlsson 
S. . Transforming growth factor-1null mice. An animal model for inflammatory 
disorders. . The American journal of pathology 146: 264–275 (1995). 
111 Grainger DJ, K. B., Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield 
PM, and Chauhan A. The serum concentration of active transforming growth factor-beta 
is severely depressed in advanced atherosclerosis. Nature Med 1: 74–79 (1995). 
112 Grainger DJ, M. D., Metcalfe JC, and Bottinger EP. Dietary fat and reduced levels of 
TGF1 act synergistically to promote activation of the vascular endothelium and formation 
of lipid lesions. Journal of cell science 113: 2355–2361 (2000). 
 
113 Mallat Z, G. A., Marchiol-Fournigault C, Esposito B, Kamate C, Merval R, Fradelizi D, 
and Tedgui A  Inhibition of transforming growth factor-beta signaling accelerates 
atherosclerosis and induces an unstable plaque phenotype in mice Circulation research 
89: 930–934 (2001). 
114 MJ, L. E. a. D. Transforming growth factor-beta: a local or systemic mediator of plaque 
stability? Circulation research 89;853-863 ( 2001). 
115 Robertson AK, R. M., Zhou X, Gorelik L, Flavell RA, and Hansson GK. Disruption of 
TGF-beta signaling in T cells accelerates atherosclerosis. The Journal of clinical 
investigation 112: 1342–1350 (2003). 
116 Gojova A, B. V., Esposito B, Cottrez F, Gourdy P, Ardouin P, Tedgui A, Mallat Z, and 
Groux H. Specific abrogation of transforming growth factor- signaling in T cells alters 
atherosclerotic lesion size and composition in mice.  . Blood 102: 4052–4058 (2003). 
117 Bennett, P. C., Silverman, S., Gill, P. S. & Lip, G. Y. Ethnicity and peripheral artery 
disease. QJM : monthly journal of the Association of Physicians 102, 3-16, 
doi:10.1093/qjmed/hcn140 (2009). 
 
 
 
